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Water-borne pathogens, which regularly cause morbidity and mortality, continue to pose 
a significant obstacle in providing safe global water to the more than 780 million people 
without access to improved water supply. Coxsackievirus, a RNA water-borne pathogen 
found worldwide, causes a range of human illnesses including diarrheal diseases and 
myocarditis. Inactivation of water-borne pathogens has been achieved using disinfectants 
such as hypochlorous acid or free chlorine. However, Coxsackievirus serotype B5 has 
demonstrated unique resistance to free chlorine disinfection compared to similar viral 
pathogens of concern, such as Adenovirus. Due to emerging regulations targeting 
disinfection byproducts of free chlorine, water utilities are switching to monochloramine 
as a secondary disinfectant to maintain a residual in distribution systems. Additionally, 
the use of free chlorine in waters contaminated with ammonia from animal and human 
waste, a commonality in developing regions with inadequate sanitation, can result in the 
formation of chloramines. The primary objective of this work is to characterize the 
kinetics of Coxsackievirus B5 inactivation using monochloramine as a function of 
temperature and pH conditions relevant to water treatment. The efficiency of 
dichloramine in viral inactivation was also assessed, and the effect of formaldehyde on 
monochloramine disinfection of Coxsackievirus B5 was tested. The findings of this work 
indicate that Coxsackievirus B5 inactivation with monochloramine is affected by both 
temperature and pH, dichloramine is a relatively ineffective disinfectant, and the presence 
of formaldehyde does not affect inactivation. The results of this work have implications 
for future disinfection design in water utilities as well as point-of-use systems for 
developing and rural regions in dire need of safe water.
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Chapter 1: Introduction 
 
This chapter provides a background to water-borne pathogens and the relevance 
of this work to providing safe global water. The objectives and scope of this research are 




Following the Millennium Summit of the United Nations in 2000, the Millennium 
Development Goals were established. Eight international development goals intend to 
improve social and economic conditions globally. Specifically, target 7.C aims to halve 
the proportion of the population without access to safe drinking water and basic 
sanitation by 2015. Revisions have changed the metric to monitor progress towards this 
goal to refer to those with access to improved water rather than safe water (United 
Nations, 2012). Currently, progress on this target with the revised metric has been 
deemed successful and projections estimate that by 2015, only 9% of the global 
population will be without access to improved water sources; an improvement upon the 
target’s required 12% (Stoler, 2012).  
 
However, studies of improved water sources in many developing regions 
demonstrate that microbial contamination is the primary reason for improved water 
sources still being unsafe for drinking (Bain et al., 2012). Therefore, this revised 
Millennium Development Goal metric likely overestimates the actual proportion of the 
population with access to water deemed safe for consumption (Stoler, 2012).    
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Water-borne pathogens cause more human disease than any other contaminant 
(Bain et al., 2012). Despite advances in drinking water treatment and disinfection, 10% of 
the global disease burden is attributable to water, sanitation, and hygiene related diseases 
(Stoler, 2012). The expected population growth from 7 billion people to 9 billion people 
by 2050 will exert increased pressure on the quality and quantity of water resources, 
making control of water-borne pathogens even more pressing (Yang et al., 2012). 
 
Inactivation of water-borne pathogens, specifically viruses, is challenging. Their 
persistence in the environment, variability, and difficulty to work with in lab 
environments has made characterizing viral response to disinfectants difficult, both 
kinetically and mechanistically. 
 
Human enteroviruses have been particularly difficult to characterize because of 
their characteristic of adaptation and evolution associated with their high mutation rates 
and quasispecies dynamics (Chen et al., 2009; Thoelen et al., 2000). Coxsackievirus, a 
human enterovirus, is a water-borne pathogen for which there are few previous 
inactivation studies. This thesis will contribute to the understanding of viral response to 
disinfectants by addressing the kinetics of Coxsackievirus inactivation with 
monochloramine in a range of relevant water quality conditions.  
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1.2 Objectives and Scope of Work 
 
1.2.1 Objectives 	  
The objectives of this research are to investigate the kinetics of Coxsackievirus 
B5 inactivation with monochloramine and to characterize the effect of relevant water 
quality parameters.  
 
1.2.2 Scope of Work 
 
In order to characterize the inactivation kinetics of Coxsackievirus B5 with 
monochloramine, this research determined:  
 
1. pH effects 
2. Temperature dependence 
3. Role of disinfection by-product formaldehyde on inactivation kinetics 
4.  Efficiency of dichloramine as a disinfectant 










Chapter 2: Background 
 
This chapter provides relevant background on Coxsackievirus and 





2.1.1 Origin  
 
Poliovirus, the causative agent of Poliomyelitis, was discovered in 1909. Through 
efforts to determine a cure to Poliomyelitis, Coxsackievirus was discovered in 1947 in 
Coxsackie, New York when isolates were obtained from the feces of polio patients and 
inoculated into newborn mice. The mice exhibited symptoms resembling non-paralytic 
polio. Based upon the varying pathology in the newborn mice, Coxsackievirus was 




Coxsackievirus is in the family Picornaviridae and genus Enterovirus. It is 
similar to Poliovirus and Rhinovirus. Coxsackievirus A is in the Human enterovirus A 
species and Coxsackievirus B is in the Human enterovirus B species (Chen et al., 2009).   
 
The viral genome of Coxsackievirus is single stranded positive-sense RNA. The 
nature of the RNA in the virus influences infection strategy. As a positive-sense RNA 
virus, Coxsackievirus RNA functions as mRNA and can be immediately translated upon 
host cell infection.    
5	  	  
2.1.3. Structure  
 
Coxsackievirus is an unenveloped virus with an icosahedral shape. It is smaller 
than other unenveloped RNA viruses and its genome has a ~7.5 kb size (Baek et al., 
2011).  
 
The icosahedral capsid is ~30 nm in diameter and is composed of 60 protomers of 
four intertwined structural proteins: VP1, VP2, VP3, and VP4. VP1-VP3 are ~270 bases 
long and are externally located to form an icosahedral lattice with 12 fivefold vertices. 
VP4 is only ~70 bases long and is located on the inner portion of the capsid to form a 
canyon depression ~1.5 nm deep (Chuan et al., 2001). The depressions are predicted to be 
the site of receptor binding for the Coxsackie-Adenovirus Receptor (CAR) protein 
(Chuan et al., 1999). These characteristics are fairly consistent for all Coxsackievirus 
strains (Hendry et al., 1999).  
 
Research suggests that virus-receptor interactions may depend on several 
receptors used in tandem. Coxsackievirus can employ multi-step attachment and 
internalization strategies that utilize several proteins (Orthopoulos et al., 2004). The 
Coxsackie-Adenovirus Receptor (CAR) protein is used for binding and internalization 
processes to enter host cells. It is a 46 kDa transmembrane glycoprotein to which specific 
residues in the viral capsid have the ability to bind. Another host cell protein used in 
Coxsackievirus binding is Decay Acceleration Factor (DAF), a 70 kDa protein that binds 
to the virus at the 2-fold and 5-fold axes of symmetry about the center of the capsid 
structure (Myers et al., 2004). 
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Figure 1. Coxsackievirus Capsid Structure (Sgro, J.V., 2013). 	  
2.1.4 Life Cycle 
 
Coxsackievirus follows a lytic viral cycle (Myers et al., 2004). Generally, the 
cycle begins when a virus attaches and injects its nucleic acid into the host cell. The viral 
nucleic acid then replicates utilizing the host cell. Once the newly synthesized viral 
nucleic acids are packaged into viral particles, they are released from the host cell.   
 
2.1.5 Health Effects 
 
Although Coxsackievirus infections can be asymptomatic, approximately 50% 
and 80% of infections can result in the onset of noticeable symptoms for Coxsackievirus 
A and B, respectively (Mena et al., 2003). These symptoms range in severity and can lead 
to chronic illness (Marosova et al., 2011). Children are especially susceptible to infection 
and the majority of those afflicted during an outbreak are below the age of 16 (Chen et 
al., 2013). Transmission is horizontal and occurs primarily via ingestion of fecal 
contaminated objects or contact with contaminated objects (Ramelli et al., 2004).    
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Coxsackievirus A has 23 serotypes and can cause fever, aseptic meningitis, 
common cold, respiratory illnesses, and flaccid paralysis. One of the most common 
illnesses associated with Coxsackievirus A is hand-foot-mouth disease, an illness 
characterized by painful red blisters that appear on the hands, feet, and mouths of those 
afflicted.  
 
Coxsackievirus B has six serotypes and is associated with pericarditis, 
pleurodynia, aseptic meningitis, myalgia and paralysis. Unlike Coxsackievirus A, 
Coxsackievirus B can lead to inflammation of myocardial tissue that interferes with 
regulatory mechanisms and leads to chronic myocardial disease (Karavidas et al., 2011). 
Infections have also been linked to the onset of type I diabetes (Wagenknecht et al., 
1991). Coxsackievirus B has also been detected in the amniotic fluid, placenta, and tissue 
of unborn children indicating the ability of pregnant women to transmit the virus 
(Marosova et al., 2011).  
 
This study used Coxsackievirus B5 because Coxsackievirus B is more virulent 
than Coxsackievirus A (Mena et al., 2003).  It is also more frequently isolated from water 
and is associated with more severe and long-term health effects (Mena et al., 2003).   
 
 
2.1.6 Distribution and Outbreaks 
 
Enteroviruses are most frequent in temperate climates and maximum circulation 
occurs during summer and may last until early autumn (Marosova et al., 2011).  Exposure 
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may be compounded in tropical climates, as similar seasonal conditions are maintained 
year-round (Yang et al., 2012).    
 
Coxsackievirus, specifically Coxsackievirus B5, differs from other Enteroviruses 
in its pattern of infection. It has an epidemic pattern of occurrence at 3-6 year intervals. 
This cycling is potentially to different genotypes surfacing or resurfacing in specific 
geographic areas (Chen et al., 2009).   
 
Coxsackievirus is common and outbreaks have occurred worldwide, both in 
developing and developed regions. Recent outbreaks have been reported in Asia, Europe, 
and North America with several simultaneous transmission chains (Baek et al., 2011; 
Chen et al., 2013; Dahling et al., 1989; Kumar et al., 2011). Outbreaks frequently occur 
in nurseries, schools, and children camps (Wang et al., 2004; Ramelli et al., 2004).  
 
 
2.1.7 Relevance in Water 
 
Population growth, extreme weather events, and continuous shifts in human 
activity impact the emergence of water-borne diseases. Water-borne diseases are caused 
by fecal contamination of water sources. Consumption of contaminated water sources 
increases risk for illness due to the presence of enteric microorganisms (Yang et al., 
2012). Coxsackievirus B5 is the most commonly isolated enterovirus serotype that can 
cause infection in humans (Chen et al., 2012). 
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In developed regions, Coxsackievirus presence in water is associated with 
sporadic outbreaks in relatively contained areas such as children camps and schools 
(Wang et al., 2004). A European outbreak at a children’s camp was caused by 
consumption of unchlorinated natural water and use of camp toilets (Ramelli et al., 2004). 
Additional outbreaks at schools have been attributed to sharing water bottles at athletic 
practice events.  
 
However, the impact of water-borne diseases is especially significant in 
developing regions. Developing regions, and some rural areas in developed regions, lack 
sufficient water access for hygienic purposes. Populous areas and poor regions have 
shown correlation with high rates of enterovirus infections. Endemic characteristics of 
many water-borne pathogens and lack of surveillance systems result in gross 
underreporting of cases (Kumar et al., 2008).  
 
High population density and low development indices, such as lack of sanitation 
and poor hygiene practice, can increase levels of viruses excreted in the environment and 
the probability of human contact with those excreted viral agents (Kumar et al., 2008). 
Feces of infected people can contain viruses for as long as eight weeks and increase the 
likelihood of viral outbreaks (Ramelli et al., 2004).   
  
 




United States Environmental Protection Agency 
 
The United States Environmental Protection Agency (USEPA) requires 
groundwater and surface water systems to achieve four-log (99.99%) removal of viruses. 
Treatment plants can achieve appropriate removal by obtaining cumulative virus 
reduction using a train of processes such as disinfection and filtration (United States 
Environmental Protection Agency, 2003). 
 
Currently, Coxsackievirus is not specifically targeted by USEPA regulations. 
However, the USEPA’s 2009 third candidate contaminant list (CCL3) includes 
Echovirus, Coxsackievirus, Adenovirus, and Calicivirus. This list features contaminants 
that are known or anticipated to occur in drinking water systems and may be regulated in 
the future under the Safe Drinking Water Act (United States Environmental Protection 
Agency, 2012).  
 
World Health Organization  
 
Health-based targets are employed to monitor microbial hazards in water sources. 
The targets rely on a combination of epidemiological data and quantitative microbial risk 
assessment (QMRA). However, these targets are not feasible or cost-effective for all 
pathogens and instead representative pathogens are used. These pathogens are identified 
based on infectivity, transmission, and occurrence in source waters among other factors. 
It is recommended to adapt targets to specific risks associated with various global areas 
(World Health Organization, 2006).  
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Using a few enteroviruses as representatives of the larger group is more beneficial 
than using fecal bacteria indicators. However, the diversity among pathogens themselves 
requires a more specific approach. The lack of simple and specific targets makes it 
increasingly difficult to control pathogen levels in developing regions where microbial 
outbreaks can occur rapidly and sporadically. As such, water quality data is not always 






Combined chlorine, or chloramines, are chlorinated compounds formed when 
chlorine reacts with organic amines. In the case of ammonia, the products of the stepwise 
process are monochloramine, dichloramine, and trichloramine. Product formation 
depends on pH conditions and the ratio of chlorine to ammonia.  
 
2.2.1 Chemical reactions 
 NH! aq +   HOCl   → NH!Cl+ H!O  (Reaction  1)   NH!Cl+ HOCl   → NHCl! + H!O  (Reaction  2)   NHCl! + HOCl   → NCl! + H!O  (Reaction  3) 
 
 
 (Snoeyink and Jenkins, 1980). 
 
 
Water treatment utilizes monochloramine, NH2Cl, which forms via Reaction 1, 
with a rate constant of k = 1.8 x 1010 M-1hr-1 (Snoeyink and Jenkins, 1980). 
Monochloramine is relatively stable at a pH range of 7-9 and a chlorine to ammonia 




The Long Term 2 Enhanced Surface Water Treatment Rule (LT2ESWTR) allows 
monochloramine to be used as a primary disinfectant (Kahler et al., 2011). The Stage 2 
Disinfectants and Disinfectant Byproduct Rule (Stage 2 DBP Rule) has established two 
standards for chloramine concentration in waters. The Maximum Residual Disinfectant 
Level Goal (MRDLG) is the maximum level for which there are no known adverse health 
effects. The Maximum Residual Disinfectant Level (MRDL) is the highest level of 
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disinfectant allowed in water. In the case of chloramines, both are set at 4 mg/L as Cl2 as 
an annual average (USEPAa, 2006).  
 
Table 1. Monochloramine exposure or CT* requirements for 4-log virus inactivation 
(USEPAa, 2006). 
 
*CT: Product of disinfectant concentration and contact time  
   
 
2.2.3 Developed Countries  
 
Clarification treatment does not always achieve required viral inactivation, so 
disinfection is a vital step in drinking water treatment plants. This has typically been 
achieved using free chlorine, widely used in water treatment as an oxidizing agent and 
disinfectant. However, regulations are becoming more stringent for free chlorine 
disinfection byproducts including four trihalomethanes (THM), and five haloacetic acids 
(HAA) (USEPAb, 2006).    
 
As such, water treatment plants are increasingly using monochloramine as a 
secondary disinfectant to minimize regulated disinfection by-product formation and limit 
biofilm growth (Kahler et al., 2010). Although monochloramine generally requires longer 
contact times than free chlorine, it is also less reactive and thus able to provide a 
Monochloramine exposure requirements for 4-log virus inactivation 
Temperature 
(°C) 1 5 10 20 25 
CT 
(mg*min/L) 2883 1988 1491 746 497 
14	  	  
consistent chlorine residual, which is advantageous for protecting water quality in 
distribution systems. However, it is important to characterize monochloramine 
inactivation of viruses, because viruses can be introduced into distribution systems due to 
infrastructure deterioration. 
 
2.2.4 Developing Regions  
 
The majority of developing regions without access to centralized water treatment 
achieve point-of-use treatment using products in liquid or solid form that employ free 
chlorine disinfection (Stoler, 2012). The presence of ammonia in these waters, due to 
inadequate sanitation, often leads to the formation of combined chlorine. This can also 
happen in rural areas of developed regions without access to centralized water treatment. 
Although at times unintentional, the formation of combined chlorine species, such as 
monochloramine, in these waters leads to disinfection kinetics that vary significantly 
from those of free chlorine.    
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2.3 Coxsackievirus B5 Inactivation Studies 
 
2.3.1 Monochloramine Disinfection  
 
Few studies have been conducted to determine the effect of monochloramine on 
Coxsackievirus B5 inactivation (Table 2). These studies have shown that 
monochloramine requires a significantly longer contact time than free chlorine in order to 
achieve inactivation.  
 
 
Table 2. Coxsackievirus inactivation with monochloramine from literature 	  
pH Temperature Log Removal 
CT (mg*min/L) 
for removal Source 
7 5°C 4 900 Cromeans et al., 2009 
8 5°C 4 1,100 Cromeans et al., 2009 
6 25°C 3 120 Kelly et al., 1960 
7 25°C 3 180 Kelly et al., 1960 
8 25°C 3 240 Kelly et al., 1960 
9 25°C 3 300 Kelly et al., 1960 
10 25°C 3 300 Kelly et al., 1960 




Monochloramine studies with another pathogen, Adenovirus, have demonstrated 
that increasing pH decreases the inactivation rate while increasing temperature increases 
the inactivation efficiency. Experiments conducted at pH 8 and 10°C required a CT of 
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~3000 mg*min/L in order to achieve 4-log removal of Adenovirus (Sirikanchana et al., 
2008). Compared to the studies on Coxsackievirus B5 inactivation with monochloramine, 
Adenovirus appears to be more resistant to monochloramine disinfection. 
 
 
2.3.2 Free Chlorine Disinfection 
 
Free chorine is currently the most widely used disinfectant both in the developed 
and developing world. More Coxsackievirus B5 inactivation studies have been conducted 
with free chlorine than with other disinfectants (Table 3). Studies indicate that the 
kinetics are slower at higher pH and lower temperatures (Vonder Haar, 2009).  
 
Compared to other pathogens, Coxsackievirus B serotypes are more resistant to 
free chlorine than most other viruses. It requires longer contact times than Coxsackievirus 






















Table 3. Coxsackievirus B5 inactivation with free Chlorine from literature 





6.03 5 2 1.7 Engelbrecht et al., 1980 
6 5 4 6.6 Sobsey et al., 1988 
7.82 5 2 2.25 Engelbrecht et al., 1980 
9.99 5 2 33 Engelbrecht et al., 1980 
10 5 4 413 Sobsey et al., 1988 
8 5 4 26.25 Sobsey et al., 1988 
9 5 4 54 Sobsey et al., 1988 
7 5 4 7.4 Cromeans et al., 2009 





2.3.3 Ultraviolet Light Disinfection 
 
Ultraviolet light inactivation of pathogens is achieved by radiation of 
contaminated water with low-pressure or medium-pressure mercury lamps. The 
inactivation rate increases with increasing fluence or the product of UV intensity and 
contact time. Compared to chemical disinfection, it has the advantage of not forming 
disinfection by products in the range of fluences typically used. However, secondary 
disinfectants are still required to maintain a disinfectant residual in the distribution 
network.   
 
18	  	  
The necessary dose to achieve 4-log inactivation of Coxsackievirus B5 is in the 
range of 28-41 mJ/cm2. This dose is higher than doses required for removal of bacteria 
such as Legionella pneumophila, and protozoan (oo)cysts such as Cryptosporidium 
parvum (USEPAa, 2006). However, it is comparable to the dose required for RNA 
viruses, with the exception of Rotavirus, which requires a much higher dose than 
Coxsackievirus B5 inactivation (Malley et al., 2004). Additionally, the dose required is 
significantly less than DNA viruses such as Adenovirus (Page and Mariñas, 2007). The 
variability in doses indicates a need for further studies on UV inactivation of 
Coxsackievirus B5 (Table 4).  
  
 
Table 4. Coxsackievirus B5 inactivation with UV from literature 
Log Removal UV dose (J/m2) Reference 
4 280 Battigelli et al., 1993 
4 360 Gerba et al., 2002 
4 325 Gerba et al., 2002 
4 240 Shin et al., 2005 
4 327 Vazquez-Bravo, 2011 
4 322 Vazquez-Bravo, 2011 
4 394 Vonder Haar, 2009 
4 406 Vonder Haar, 2009 
 
 
2.3.4 Ozone Disinfection 
 
Ozone is a strong oxidizing agent that is added to water through bubble diffusion. 
It is an effective disinfecting agent for bacteria and viruses alike, and achieves 
inactivation very rapidly. Water utilities typically generate ozone on-site. It is added to 
the water through bubble diffusion. 
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There are few studies about the effect of ozone on inactivation of Coxsackievirus. 
This may be attributed to the extremely rapid kinetics of inactivation that require very 
low doses of ozone as well the use of a stop-flow reactor in order to characterize the rate 
of inactivation. A prior study achieved 3.68 log removal at 1°C at a CT of 0.0046 







Chapter 3: Experimental Materials and Methods  
 
This chapter presents the experimental matrix that was used for the scope of this 
research. The chapter also discusses the materials and methods that were used for all 
experimental procedures in this research.  
 
3.1 Experimental Matrix  
 
In order to determine pH and temperature effects on the kinetics of 
Coxsackievirus B5 inactivation with monochloramine, experiments were conducted at a 
range of temperatures and pH conditions relevant to water treatment (Table 5). The 
monochloramine concentration was studied within the range of 3.75 mg/L as Cl2 to 21.46 
mg/L as Cl2.   
 
Table 5. Matrix of target pH and temperature inactivation conditions 
pH 6 pH 7 pH 8 pH 9 pH 10 
- - - 5°C - 
10°C 10°C 10°C - 10°C 
20°C 20°C 20°C - 20°C 
30°C 30°C 30°C - 30°C 
 
  
 3.2 Materials and Methods 
 
3.2.1 Preparation of host cell monolayer 
 
Buffalo Green Monkey Kidney (BGMK) cells were used as the host cell for all 
Coxsackievirus experiments conducted in this work. The method of BGMK monolayer 
preparation was done in accordance with the USEPA Manual of Methods for Virology 
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(EPA/600/4-84/013, 1987). BGMK cells were ordered from Diagnostic Hybrids and 
delivered in a temperature-controlled package.  
 
Upon arrival, individual tubes of BGMK cells were treated with 0.5 mL of 
trypsin-EDTA to assist in cell detachment and decrease the potential of cell clumping. A 
cell culture volume of 3 mL was then collected and added to 7 mL of cell media in 75 
cm2 tissue-culture flasks with a canted neck and plug seal cap.  
 
The cell media mentioned above was a 50/50 mixture of Minimum Essential 
Medium (with Hank’s salts and L-glutamine, but without sodium bicarbonate) and 
Leibovitz’s L-15 (with L-glutamine) and 0.75 g sodium bicarbonate per liter, 10% fetal 
bovine serum, 1% Penicillin/Streptomycin antibiotics, and 0.1% of Amphocyterin B.  
 
Flasks containing cell suspension were incubated at 37°C until cell confluence 
reached 80-90%, which usually took 5-8 days. Confluence was verified using an 
Olympus IX51 inverted microscope. Once 80-90% confluence was reached, the BGMK 
monolayer was ready for cell passage.  
 
3.2.2 Cell Passage  
 
During cell passage, the cells were removed from the original flasks, diluted, and 
transferred to new flasks to be used in subsequent cell culture and/or virus viability 
assessment for experimentation. Typically, about 75% of the cell solution was used for 
virus viability assessment and the remaining 25% was used for cell culture.  
 
22	  	  
The cell media was aspirated from the flasks followed by the addition of 3 mL of 
Dulbecco’s Phosphate Buffer Solution to rinse the cells in the monolayer. The cells were 
then detached by adding 1.5 mL of trypsin-EDTA to the flasks for 15-20 minutes, during 
which the flasks were intermittently tapped and/or rocked.  Once detachment occurred, 
the cells were collected and diluted to desired concentrations using cell media. Cells to be 
used for subsequent cell passage were transferred to 75 cm2 canted-neck plug seal tissue-
culture flasks and grown as before. Cells to be used for virus viability assessment were 
transferred to 25 cm2 canted-neck plug seal tissue-culture flasks and incubated at 37°C 
for 3-5 days, at which point they had reached 90-100% confluence and were ready for 
virus viability assessment.  
 
 
3.2.3 Virus Propagation 
 
All work in this study regarding Coxsackievirus followed Biosafety Level 2 
procedures for which necessary training and certification was obtained through the 
University of Illinois Division of Research Safety. This study used Coxsackievirus B5 
Faulkner (VR-185), which was obtained from the American Type Culture Collection 
(ATCC, Virginia). All virus stocks were propagated from lot # 58105518. Virus stock 
was purified after three rounds of viral propagation. 
 
Prior to viral inoculation, a BGMK cell monolayer was grown on a 75 cm2 
canted-neck plug seal tissue-culture flask for 5-8 days. For the first round of viral 
propagation, the flask was inoculated with 0.1 mL of virus stock and incubated at 37°C. 
The cultures were examined after 3-4 days to ensure cell lysis and death and then frozen 
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at -20°C and allowed to thaw at room temperature. This freeze-thaw cycle was conducted 
three times.  
 
The infected monolayer was then transferred into 50 mL centrifuge tubes and 
centrifuged with Thermo Electron Corporation Forma 400 centrifuge in the range of 2-
2.5 rpm for approximately 12 minutes to form a pellet by separating extracellular material 
and artifacts from the virus. The pellet was resuspended in cell media after removal of the 
supernatant and then frozen at -80°C. 
 
For the second round of viral propagation, the centrifuge tube was thawed and 2 
mL was inoculated into a 75 cm2 canted-neck plug seal tissue-culture flask with 8 mL of 
cell media. The cultures were examined to ensure cell lysis, freeze-thawed, and 
centrifuged as in round 1. After the third round of viral propagation, the stock was 
purified.  
 
3.2.4 Virus Suspension Purification 
 
The virus stock was purified and cleaned using a two-step filtration procedure. 
First, a 0.22-micron pore sized membrane filter and vacuum filtration apparatus removed 
particles larger than the virus. To reduce sorption losses and ensure the integrity of the 
membrane, the membrane was very slightly coated with sterile Fetal Bovine Serum. 
Sterile nano-pure water was slowly passed through the system followed by the virus 
stock. The virus filtrate was collected for use in the second filtration step.  
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The second filtration process used a 50 kD ultrafiltration membrane installed in an 
Amicon cell model 8400 with a cell diameter of 76 mm to remove particles smaller than 
the virus. The Amicon cell was filled with 50 mL of virus filtrate and pressurized to 15 
psi. When the volume inside the cell reached 10-15 mL, sterile 1 mM carbonate buffer 
solution (CBS, pH 8.3) was added to bring the volume back to 50 mL. This process was 
repeated until the filtrate was clear and lost its pink tint. The final Coxsackievirus stock 
solution was aliquoted into 1 mL criovials and stored at -80°C. 
 
3.2.5 Virus Viability Assessment    
 
A soft agar overlay plaque assay on a BGMK cell monolayer grown in 25 cm2 
tissue-culture flasks was used to assess Coxsackievirus viability.  
 
On the day of the plaque assay, growth media was aspirated from the flasks and 
replaced with 1 mL of maintenance medium, a 50/50 mixture of MEM (with Hank’s salts 
and L-glutamine, without sodium bicarbonate) and Leibovitz’s L-15 (with L-glutamine), 
and 0.75 g sodium bicarbonate per liter.  
 
The maintenance medium was also used as the dilution broth for the serial ten-
fold dilutions.  The monolayer was then inoculated with 0.85 mL of virus suspension. To 
distribute the suspension evenly over the cell monolayer, the inoculated flasks were 
slowly rocked at room temperature for 60 minutes and then allowed to sit for 30 minutes.  
 
For a plaque assay sufficient for 20 individual 25 cm2 flasks, 100 mL of nano-pure 
water with 3 g of agar was autoclaved. The autoclaved agar was kept in a water bath at 
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60°C until use. The overlay medium was prepared with 83 mL 2X MEM, 3 mL FBS, 1 
mL magnesium chloride, 1 mL Penicillin/Streptomycin, 0.2 mL fungicide, 6 mL of 7.5% 
(w/v) sodium bicarbonate solution, and 0.75 mL neutral red solution, added in that order. 
Although the component order may be modified, the sodium bicarbonate solution should 
be added second to last to prevent equilibration with the environment and the neutral red 
solution should be added last to prevent dye decay.  
 
After the overlay medium was added to the agar, 9 mL of the combined overlay 
solution was added to the inoculated flasks, which were then allowed to harden in the 
dark for 10-15 minutes. Once dry, the flasks were wrapped in aluminum foil to prevent 
dye exposure to the light. The flasks were incubated upside down at 37°C. Plaques were 
quantified on the third and fourth day after agar overlay. Flasks with 15-250 plaques were 
used for calculation of virus concentration.  
 
3.2.6 Disinfection Experiments 
 
3.2.6.i Controlling Temperature and pH  
 
This study used carbonate buffer solution (CBS) with controlled water quality 
parameters of pH and temperature. The carbonate buffer used in this study was prepared 
by autoclaving 0.084 g of sodium bicarbonate added to 1 L of nano-pure water.  
 
Batch reactor conditions were maintained by immersing the reactors in a 
recirculating water bath set at the desired temperature. The temperature was monitored 
closely throughout the duration of the experiment to minimize temperature fluctuation. 
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The pH was primarily controlled using the carbonate system. The reactors were sparged 
with carbon dioxide gas to decrease the pH. If the gas lowered the pH beyond the target 
pH, the reactor was allowed to stir while open to reach the target pH. Sodium hydroxide 
solution was added to increase the pH beyond ~8.3.  
 
3.2.6.ii Glassware Preparation  	  
All experiments in this study used amber glassware reactors to minimize the 
potential effect of surrounding light on experimentation. To ensure that glassware was 
chlorine demand-free, the reactors were chlorinated with 0.1% bleach overnight and 
rinsed thoroughly with deionized water. Once dry, all glassware was autoclaved.  
   
3.2.6.iii Monochloramine Formation   	  
Three reactors of equal volume were used, one as a control reactor and the other 
two were used to prepare the monochloramine.  
 
The two reactors for monochloramine formation were filled with 50 mL of sterile 
1 mM carbonate buffer solution. To achieve an ammonium:chlorine ratio of 4:1 and a 
target concentration of 10 mg/L, 4.78 milligrams of ammonium chloride was added to 
one reactor and 0.010 mL of sodium hypochlorite was added to the other. To ensure 
formation of only monochloramine, 5 mL of the sodium hypochlorite solution was slowly 
added to the ammonium chloride reactor every ten minutes. Once the entirety of the 
sodium hypochlorite solution was added, the resulting solution was allowed to stir for at 
least ten additional minutes before samples for DPD measurement were taken.   
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The third reactor was a control reactor containing 100 mL of sterile 1 mM 
carbonate buffer solution. This reactor was used to characterize any viral inactivation 
attributable to pH and temperature conditions and not the monochloramine disinfectant.    
 
3.2.6.iv Dichloramine Formation  
 
A dichloramine experiment was conducted to determine the effect, if any, of 
dichloramine on inactivation of Coxsackievirus B5. Dichloramine was prepared by 
forming a monochloramine solution at pH 8, 20°C with a target concentration of 10 mg/L 
as Cl2. The pH was then lowered to a pH of 3.5-4 using perchloric acid. The solutions 
were discarded if the pH fell below 3 during preparation. Below a pH of 3, trichloramines 
are produced and the dichloramine is no longer stable and decomposes rapidly. 
 
The reactor was allowed to equilibrate with the atmosphere at 20°C for a few 
minutes until the pH rose to 6. This condition was selected in order to maintain 
comparable experimental conditions to other experiments conducted in this study.  
 
3.2.6.v Formaldehyde Formation 
 
Formaldehyde experiments were conducted to determine if the presence of 
formaldehyde would affect monochloramine inactivation kinetics of Coxsackievirus B5. 
The targeted concentration of formaldehyde was 10-3 M. Such a high concentration was 
selected to determine if there was any intrinsic inactivation of Coxsackievirus B5. A 
formaldehyde stock solution was prepared by adding 0.0796 mL of formaldehyde to 100 
mL of autoclaved nano-pure water. The solution was allowed to stir for 10 minutes and 
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then stored overnight at 4°C. Formaldehyde experiments were conducted at pH 7.25 and 
25°C to maintain stability of the solution. 
 
3.2.6.vi Reactor Sampling 
 
At time zero, both the experimental and control reactors were dosed with 0.5 mL 
– 1 mL of Coxsackievirus stock to achieve a target concentration within the range of 104-
106 pfu/mL for the various stocks used.  A magnetic stir bar was added to each reactor to 
achieve continuous mixing conditions. An initial 1 mL sample was withdrawn from the 
control reactor to determine the initial virus concentration, N0. To assess virus viability at 
target CT values, 1 mL samples were withdrawn from the monochloramine reactor and 
quenched with 0.1 mL of 0.1% sodium thiosulfate. The sampling time was noted as the 
time of quenching. Contact times were selected based on a target of six data points 
covering the target range of zero to four log virus inactivation. Virus viability assessment 
of all samples was conducted immediately after the conclusion of the experiment.   
 
3.2.6.vii Chlorine Analysis 
 
Chlorine concentration in the samples was analyzed by the DPD colorimetric 
method using a UV-vis spectrophotometer set at 515 nm. For a dilution factor of 10, a 0.3 
mL sample was withdrawn from the reactor and added to 2.7 mL of CBS buffer. This was 
mixed with 0.15 mL of phosphate buffer solution, 0.15 mL of DPD (diethyl-p-
phenylenediamine), and 0.0010 mL KI (potassium iodide).  For the dichloramine 
experiment, the same method was used except excess KI was added and the cuvette was 
allowed to sit for two minutes before obtaining a reading.  
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Absorbance readings were correlated to chlorine concentration with the 
expression: 














Ch. 4 Results and Discussion 
 
This chapter presents the data obtained from this study and a discussion of the 
various factors studied and how they influenced Coxsackievirus B5 inactivation kinetics. 
 
4.1 Monochloramine Disinfection 
 
Inactivation kinetics for the experimental conditions demonstrated pseudo-first 
order kinetics without an observable lag phase. Therefore, the Chick-Watson expression 
(eq. 2) was used to fit the kinetics and calculate the inactivation rate constant.  
 !!! = e!!"# (Equation 1) 
 
where  
!!! is the fraction of viable Coxsackievirus plaques quantified after time t of exposure to 
monochloramine k is the second order inactivation rate constant in L/(mg*min) 
CT is the product of concentration of disinfectant and time of exposure in (mg*min)/L 
 
4.1.1 Rate Constants and Required CT 	  
 
Using equation 1, the inactivation rate constant, k, was calculated for each 
experimental set (Appendix A). Table 6 is a summary of the calculated inactivation rate 





Table 6. Inactivation rate constants for experimental conditions 
Inactivation Rate Constants, k (L/(mg*min)), for Experimental Conditions 
 pH 6 pH 7 pH 8 pH 10 
10°C 0.018 ± 0.003 0.013 ± 0.002 0.009 ± 0.002 0.004 ± 0.0006 
20°C 0.069 ± 0.01 0.070 ± 0.020 0.020 ± 0.004 0.013 ± 0.002 
30°C 0.166 ± 0.026 0.208 ± 0.107 0.073 ± 0.017 0.048 ± 0.021 
 
 
 The inactivation rate constants were used to obtain CT values required for 4-log 
Coxsackievirus B5 removal. Table 7 is a summary of the CT values for all experimental 
conditions of this research.  
 
Table 7. CT required for 4-log Coxsackievirus B5 removal 
CT Required (mg*min/L), for 4-log Coxsackievirus Removal 
 pH 6 pH 7 pH 8 pH 10 
10°C 532 ± 98 705 ± 90 1103 ± 252 2686 ± 443 
20°C 137 ± 24 135 ± 21 477 ± 76 719 ± 96 
30°C 57± 8 68 ± 67 131 ± 27 213 ± 75 
 
 A comparison of CT values obtained in this study and those in the LT2ESWTR 
reveal that four-log Coxsackievirus removal would be achieved under all conditions 
when complying with LT2ESWTR except at pH 10, 10°C. The United States 
Environmental Protection Agency requires a CT of 1491 mg*min/L, which this research 
found to be insufficient for four-log Coxsackievirus B5 removal.   
4.1.2 Effect of Monochloramine Concentration on Inactivation Rate  
 
The concentration of monochloramine was varied to determine if consistent 
inactivation kinetics would be obtained, regardless of disinfectant concentration (i.e. 
validity of equation 1).  Monochloramine concentration was varied at 20°C for pH 
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conditions 6, 7, 8, and 10. Inactivation was not affected by concentration variation and 
the kinetics remained consistent for all pH conditions. This is illustrated with the 
inactivation data at pH 8, 20°C, shown in Figure 2. This figure demonstrates that the 
same kinetics are obtained at 5 mg/L as Cl2 and 10 mg/L as Cl2 for which the rate 
constants were calculated to be 0.017 and 0.018 L/(mg*min), respectively. The 
inactivation data demonstrating the effect of monochloramine concentration on the 




Figure 2. Inactivation of Coxsackievirus B5 with monochloramine at pH 8, 20°C, and 




4.1.3 Effect of Temperature on Inactivation Rate 
 
This study investigated the effect of temperature on the inactivation kinetics of 











CVB5	  Inaction:	  pH	  8,	  20C	  	  
10	  mg/L	  as	  Cl2	  5	  mg/L	  as	  Cl2	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temperature from 10°C to 30°C increased the inactivation rate for all pH conditions. 
Depending on the pH condition, the inactivation rate constant increased by a factor of 7-
16. 
 
The greatest temperature effect was observed at pH 7, at which increasing the 
temperature from 10°C to 30°C resulted in increasing the inactivation rate by a factor of 
16 (Figure 3). At pH 6 and pH 10, similar but less significant temperature trends were 
observed.  For both of the aforementioned conditions, the temperature increase from 
10°C to 30°C increased inactivation rates by a factor of 9, with only slight dominance in 
the increase at lower temperatures. Figures for pH 6 and pH 10 inactivation data can be 
found in Appendix D.  
	  
Figure 3. Temperature effect on the inactivation of Coxsackievirus B5 with 
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The weakest temperature dependence was observed at pH 8. Increasing the 
temperature from 10°C to 30°C resulted in an increase in the inactivation rate by a factor 
of 7. Additionally, pH 8 was the only pH condition in which the inactivation rate 




Figure 4. Temperature effect on the inactivation of Coxsackievirus B5 with 
monochloramine at pH 8 
 
The temperature dependence trends of Coxsackievirus B5 are consistent with the 
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  mg/L	  
35	  	  
this research also indicate that the magnitude of temperature dependence of 
Coxsackievirus B5 is greater than that of Adenovirus, for the same disinfectant 
(Sirikanchana et al., 2008). 
 
It has been suggested that viruses are less sensitive to high temperature changes in 
complex matrix systems as opposed to the sterile buffered system that was used for this 
study (Bertrand et al., 2012). Natural waters may have a high chlorine demand, requiring 
longer contact times to achieve Coxsackievirus inactivation. Additionally, water 
impurities can offer protective cover to viruses and viral resistance can vary in the 
presence of complex mixtures of water constituents.  
 
Faster inactivation observed at higher temperatures may be indicative of the 
sensitivity of Coxsackievirus B5 protein reactivity to temperatures above a specific 
threshold. For the majority of pH conditions studied in this research, that temperature 
appears to be between 10°C to 20°C.    
  
4.1.4 Effect of pH on Inactivation Rate 
 
This study investigated the effect of pH on the inactivation kinetics of 
Coxsackievirus B5 by monochloramine by performing experiments at pH 6, pH 7, pH 8, 
pH 10, on the inactivation kinetics of Coxsackievirus B5. Increasing the pH from 6 to 10 
decreased the rate of inactivation by a factor of 4-5. For all temperature conditions 
evaluated, the inactivation kinetics at pH 6 and pH 7 were nearly identical. At the higher 
temperatures of 20°C and 30°C, the most significant pH effect occurred when increasing 
the pH from pH 7 to pH 8 (Figs. 5, 6). The effect was most significant at 20°C, where the 
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increase from pH 7 to pH 8 alone decreased inactivation kinetics by a factor of 4. 
Inactivation kinetics for pH 8 and pH 10 were nearly identical.   
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Figure 6. pH effect on the inactivation of Coxsackievirus B5 with monochloramine at 
30°C 
 
However, at the investigated lower temperature of 10°C, the inactivation kinetics 
at pH 6 to pH 8 were very similar and the decrease in inactivation kinetics occurred 
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Figure 7. pH effect on the inactivation of Coxsackievirus B5 with monochloramine at 
10°C 
 
Similar pH trends of decreasing inactivation rates with increasing pH have been 
demonstrated with other viruses, such as Adenovirus. Specifically, at low temperatures, 
Coxsackievirus B5 is similarly susceptible to monochloramine disinfection at a broader 
range of pH conditions. However, at higher temperatures, Coxsackievirus B5 inactivation 
requires significantly less disinfectant contact time than that required by Adenovirus, 
particularly at pH conditions below pH 7.   
It is suggested that the pH dependence is attributed to the varying interactions 
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  Inactivation	  at	  10°C	   pH	  6,	  8.2	  mg/L	  pH	  6,	  8.4	  mg/L	  pH	  6,	  9.0	  mg/L	  pH	  7,	  4.8	  mg/L	  pH	  7,	  8.7	  mg/L	  pH	  7,	  9.1	  mg/L	  pH	  8,	  5.1	  mg/L	  pH	  8,	  6.5	  mg/L	  pH	  8,	  7.5	  mg/L	  pH	  8,	  8.9	  mg/L	  pH	  8,	  9.1	  mg/L	  pH	  10,	  7.5	  mg/L	  pH	  10,	  8.84	  mg/L	  pH	  10,	  11.96	  mg/L	  pH	  10,	  13.5	  mg/L	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and pH 8 at 20°C and 30°C may indicate a change in protein conformation at these 
conditions that is affected more by pH rather than temperature. These viral proteins, the 
majority of which are located on the outside of the virus, are exposed to the bulk 
disinfectant more than the proteins located within the virus depressions. Protein 
conformation itself may inactivate Coxsackievirus or increase disinfectant access to more 
integral inner viral components.   
 
4.2 Formaldehyde Experiment 
 
Formaldehyde can occur in drinking water sources when natural organic material 
is oxidized during chlorination as a result of leaching from plastics. Additionally, 
formaldehyde can react with monochloramine present in water to form the relatively 
stable organic chloramine, N-chloroaminomethanol, which can contribute to inactivation 
(Pedersen et al., 1999). This can be of concern for both developing and developed 
regions. An experiment was conducted with a concentration of 10-3 M formaldehyde at 
pH 7.25 and 25°C. This concentration is well above levels of formaldehyde that can 
typically be found in water sources. 
 	  
4.2.1 Effect of Formaldehyde on Inactivation Rate 
 
Even at the high formaldehyde concentration, 10-3 M of formaldehyde, the 
inactivation kinetics of the formaldehyde experiment was slower than that for an 
experiment at identical conditions without formaldehyde (Figure 8). The inactivation rate 
constants were calculated to be 0.118 and 0.184 ± 0.021 L/(mg*min) with and without 





Figure 8. Effect of formaldehyde on the inactivation of Coxsackievirus B5 with 
monochloramine 	  	  
4.3 Dichloramine Experiment 
 
A dichloramine experiment was conducted at pH 6 and 20°C to ensure that any 
observed inactivation of Coxsackievirus B5 was attributable to monochloramine and not 
to other chloramine species.  
 
4.3. 1 Effect of Dichloramine on Inactivation Rate  
 
In the presence of dichloramine, only 1-log removal was achieved at a CT of 370 




















CVB5	  Inactivation	  at	  pH	  7.25,	  25°	  C	  
8.51	  mg/L	  .001	  M	  Formaldehyde,	  10.9	  mg/L	  	  10	  mg/L	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and 20°C, 4-log removal was achieved at a CT of 133 (mg*min)/L. This confirms that 
dichloramine is not an effective disinfectant. It also demonstrates that the inactivation 
observed in this research is primarily due to the effect of monochloramine on 
Coxsackievirus B5.     
 	  
4.4 Effect of CVB5 Stock on Inactivation Rate 
 
4.4.1 Effect of CVB5 Stock Purification on Inactivation Rate 
 
Coxsackievirus B5 stock purification is done prior to experimentation to ensure 
that observed inactivation kinetics are primarily due to the interaction between the 











CVB5	  Inactivation	  at	  pH	  6,	  20°	  C	  
Monochloramine,	  9	  mg/L	  
Monochloramine,	  7	  mg/L	  
Monochloramine,	  3.8	  mg/L	  
Dichloramine,	  8.40	  mg/L	  	  
Figure 9. Comparison of the kinetics of Coxsackievirus B5 inactivation with 
monochloramine and dichloramine at pH 6, 20°C 
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state. Therefore, experiments were conducted using an unpurified Coxsackievirus B5 
stock to determine whether cellular debris and other artifacts influence the efficiency of 
monochloramine against Coxsackievirus B5. Unpurified stock experiments were 
conducted at pH 8, 20°C (Figure 10). For this condition, no significant difference was 
observed between using a purified and unpurified virus stock. The rate constants for the 
unpurified and purified Coxsackievirus B5 stock were 0.027 and 0.020 ± 0.004 




Figure 10. Comparison of the kinetics of purified and unpurified Coxsackievirus B5 
inactivation with monochloramine at pH 8, 20°C 
 
 
This research revealed that unpurified Coxsackievirus and purified 


















CVB5	  Inactivation	  at	  pH	  8,	  20C	   PuriHied	  Stock,	  5	  mg/L	  PuriHied	  Stock,	  8.6	  mg/L	  PuriHied	  Stock,	  10.0	  mg/L	  PuriHied	  Stock,	  12.05	  mg/L	  PuriHied	  Stock,	  12.1	  mg/L	  UnpuriHied	  Stock,	  10.5	  mg/L	  UnpuriHied	  Stock,	  12.1	  mg/L	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purification process does not weaken the virus or render it more susceptible to 
disinfection. This correlates with previous bacterial studies that found lab-cultured 
bacteria and naturally occurring bacteria in identical matrices and experimental 
conditions responded similarly to monochloramine disinfection (Shang et al, 2005).  
 
4.4.2 Effect of CVB5 Stock Age on Inactivation Rate 
 
Various Coxsackievirus B5 stocks were used throughout the duration of this 
study. The effect of the stock age on inactivation rate and the ability to obtain target virus 
concentration during experiments was measured. Stocks 5, 6, 8, 9, and 10 were used in 
this research. Stocks 1-4 were used in previous Coxsackievirus B5 studies. No 
Coxsackievirus B5 was detected in stock 7, so it was not used for experiments. The 
majority of Coxsackievirus B5 stocks were used within two months of purification. The 
oldest stock used was 11 months old. The age of the stock age had no effect on 
inactivation rate and inactivation data was reproducible regardless of the stock used or 
the age of the stock.  
 
In order to determine the effect of stock age on the ability to obtain target 
concentration of the virus, N0 values from experiments were compared to the targeted 
concentration as calculated based upon the initial concentration of the stock. A virus 
stock summary for individual experiments can be found in Appendix B.  The results were 
varied and no clear trend was observed linking a decrease of Coxsackievirus B5 stock 
concentration to increasing age. Figure 11 demonstrates the variance of Coxsackievirus 
B5 stock concentration over a period of three months. Similar figures for the remaining 
stocks are in Appendix E.  
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Figure 11. Coxsackievirus B5 stock 6 concentration over time 
 
Target concentration percentages greater than 100% indicate that the N0 
concentration observed for that experiment was greater than the Coxsackievirus 
concentration observed when the stock was originally assessed.   Variation could be 
attributed to the aggregation tendency of Coxsackievirus B5 at all pH conditions relevant 
to water treatment (Jensen et al, 1980).    
 
These findings indicate that if stocks are frozen in appropriate conditions, they 
will continue to have viable viruses without a trend of decreasing concentration. 
However, due to the variable nature of obtained target Coxsackievirus concentrations, it 
is recommended to measure the virus concentration of Coxsackievirus B5 stocks stored 
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Chapter 5: Conclusions and Recommendations 
 
This chapter summarizes the findings of this work and discusses the implications 
of this research for global safe water. Recommendations for future work are also 
discussed. 
 
5.1 Summary of Findings 	  
This research characterized the kinetics of Coxsackievirus B5 inactivation with 
monochloramine under a range of temperature and pH conditions relevant to water 
treatment. Optimal inactivation conditions of Coxsackievirus B5 were found to be at high 
temperature and low pH conditions. Compared to free chlorine inactivation, 
monochloramine inactivation required an order of magnitude longer contact time. The CT 
values obtained in this study varied slightly from previous studies of monochloramine 
inactivation of Coxsackievirus B5 but exhibited similar pH and temperature trends.  
Results revealed that increasing the pH from 6 to 10 resulted in decreasing rate.  
For experiments conducted at 20°C and 30°C, the change in kinetics was dominated by 
the pH increase from pH 7 to pH 8. At the lower temperature of 10°C, the decrease in 
kinetics was observed when increase the pH from 8 to 10.  
Coxsackievirus B5 exhibited strong temperature dependence and the inactivation 
rate was significantly increased for all pH values when the temperature was increased 
from 10°C to 30°C. All of the pH conditions, except for pH 8, exhibited a greater 
increase in inactivation kinetics when the temperature was increased from 10°C to 20°C, 
rather than from 20°C to 30°C. 
46	  	  
The presence of the disinfection by-product formaldehyde did not affect 
inactivation significantly. The results of this research also revealed that the age of the 
Coxsackievirus B5 stock had negligible effect on the inactivation kinetics.  
 
Dichloramine was found to be a weaker disinfectant compared to 
monochloramine for inactivation of Coxsackievirus B5. This indicates that observed 




5.2.1 Developed Regions 	  
As water utilities continue to evaluate switching from free chlorine to 
monochloramine in their systems, it is important to consider the effect of such a change. 
Monochloramine, while still an effective disinfectant against Coxsackievirus B5, requires 
longer contact times than free chlorine. These times are significantly longer at low pH 
and low temperature conditions. As the kinetics vary greatly with condition variance, 
utilities will need to monitor these changes and adjust contact time as needed. 
Maintaining low pH conditions and high temperatures will achieve the fastest 
inactivation of Coxsackievirus B5.  
 
 Current monochloramine regulations from the United States Environmental 
Protection Agency regarding required CT values for four-log virus removal, do not 
ensure Coxsackievirus B5 removal at all conditions. The CT values obtained in this 
research were less than those required of the United States Environmental Protection 
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Agency for all conditions, except pH 10 at 10°C. This should be considered as 
regulations are modified in the future, particularly since other viruses, such as 
Adenovirus, are even more resistant to monochloramine than Coxsackievirus B5.  
 
5.2.2. Developing and Rural Regions 
 
For many developing and rural regions that lack access to centralized water 
treatment, point-of-use water treatment has been shown to be an effective strategy in 
minimizing the outbreak of water-borne diseases and diarrheal illness (Doocy and 
Burnham, 2006). The majority of recommended point-of-use water treatment systems for 
these regions employs a disinfection step that relies on free chlorine, whether as a 
distributable sachet or locally produced hypochlorous acid solution.  
 
However, the sporadic high levels of ammonia in these waters form combined 
chlorines upon addition of free chlorine. As demonstrated in this research, inactivation 
kinetics of monochloramine for pathogens can vary significantly compared to those of 
free chlorine. Much longer contact times are required for sufficient viral removal in the 
case of monochloramine being the predominant disinfectant. People in these regions who 
follow the instructions on their point-of-use product can continue to fall ill to water-borne 
diseases because of inadequate viral removal. For many communities, the result can be 




The results of this research can be used to design point-of-use treatment systems 
and recommendations that will provide adequate control of Coxsackievirus B5. The 
significant temperature dependence of Coxsackievirus B5 can be used to increase the 
time required for inactivation time significantly, as many developing regions, particularly 
those in regions around the equator, have warm climates and temperatures easily exceed 
30°C.   
 
5.2.3 Future Recommendations 
It is recommended that future work conduct Coxsackievirus B5 inactivation with 
monochloramine in real water conditions. This will verify whether the pH and 
temperature trends demonstrated in this work apply in complex matrix systems.  
 
Future work is also recommended in the area of mechanisms of Coxsackievirus 
B5 inactivation with monochloramine. Understanding the structure of Coxsackievirus B5 
and the interaction of Coxsackievirus components and proteins with disinfectants, such as 
monochloramine, can provide insight into the pH and temperature trends exhibited in this 
research. 
 
On a broader scale, utilities are switching to monochloramine use because it has 
fewer regulated disinfection by-products than free chlorine. However, the health effects 
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Date pH Temperature [NH2Cl] (mg/L as Cl2) K Comments
12/17/2011 8 30°C 7.96 0.074
12/17/2011 10 30°C Not used; insufficient data points
1/26/2012 8 5°C 8.49 0.005
2/2/2012 9 5°C 11.26 Not used; No No value 
2/9/2012 8 20°C 8.64 0.017
3/12/2012 8 20°C 7.69 0.049 Not used; unknown stock
7/2/2012 7.25 25°C 10.93 0.118 Formaldehyde
7/9/2012 7.25 25°C 8.51 0.164
7/25/2012 7.25 25°C 10.13 0.184
7/30/2012 7.25 25°C 8.72 0.205 Formaldehyde
8/14/2012 6 30°C 8.29 0.148
8/16/2012 7 30°C 7.83 0.38
9/21/2012 6 30°C 8.8 0.208
9/28/2012 6.5 20°C 8.29 0.065
10/5/2012 6 20°C 9.29 0.066
10/12/2012 7 20°C 9.58 Not used; insufficient data points
10/15/2012 6.5 20°C 10.8 Not used; insufficient data points
10/18/2012 6 20°C 8.06 0.076
10/22/2012 6.5 10°C 11.5 0.023
10/24/2012 7 20°C 6.55 0.083
11/27/2012 8 20°C 11.03 0.048
11/27/2012 8 20°C 11.46 Unpurified stock. Not used.
12/6/2012 8 20°C 10.54 0.027 Unpurified stock.
12/18/2012 8 20°C 12.12 Unpurified stock. Not used; insufficient data points.
12/24/2012 8 20°C 9.97 0.019
12/24/2012 10 20°C 10.54 0.011
12/29/2012 8 20°C 12.06 0.025
12/29/2012 10 20°C 10.61 0.013
1/1/2013 10 20°C 21.46 0.016
1/8/2013 8 20°C 12.05 0.018
1/8/2013 10 20°C 7.77 0.012
1/15/2013 8 30°C 7.6 Not used; insufficient data points.
1/15/2013 10 30°C 7.03 0.041
1/16/2013 8 30°C 10.63 0.061
1/16/2013 10 30°C 7.58 0.043
1/20/2013 7 30°C 7.4 0.218 Not used; insufficient data points
1/20/2013 7 30°C 4.53 0.223
1/22/2013 6 30°C 6.3 0.147
1/22/2013 6 30°C 7.89 0.153
1/28/2013 8 30°C 9.74 0.06
1/28/2013 10 30°C 10.77 0.031
1/29/2013 6 30°C 5 0.174
1/29/2013 7 30°C 6.51 0.182
2/4/2013 8 30°C 5.11 0.097
2/4/2013 8 30°C 5.27 0.17 Not used; insufficient data points.
2/6/2013 7 30°C 9.33 0.045
2/6/2013 7 30°C 9.52 0.201
2/10/2013 7 20°C 6.23 0.061
2/10/2013 6 20°C 7.13 0.078
2/10/2013 6 20°C 3.75 0.071





Note: Experiments with insufficient data points are experiments in which less than four 
data points were obtained. Outlier data sets were determined using Dixon’s Q-test for 
outliers and were not included in the inactivation rate constant calculations.  
Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) K Comments
52 2/12/2013 8 20°C 10.38 Not used; insufficient data points.
53 2/12/2013 10 20°C 11.1 0.013
54 2/13/2013 8 10°C 7.54 0.009
55 2/13/2013 10 10°C 7.54 0.004
56 2/14/2013 7 10°C 4.77 0.012
57 2/18/2013 7 20°C 6.03 0.064 Not used; Outlier data set
58 2/18/2013 8 20°C 5.04 0.017
59 2/20/2013 8 30°C 5.34 0.05 Not used; insufficient data points.
60 2/20/2013 8 30°C 5.03 0.055
61 2/21/2013 8 10°C 6.77 0.013
62 2/26/2013 8 10°C 8.87 0.007
63 3/1/2013 6 10°C 8.43 0.022
64 3/6/2013 8 10°C 9.08 0.007
65 3/11/2013 10 10°C 13.5 0.004
66 3/11/2013 8 10°C 6.53 0.008
67 3/13/2013 7 10°C 8.67 0.013
68 3/13/2013 7 10°C 9.1 0.016
69 3/14/2013 6 10°C 8.95 0.015
70 3/14/2013 6 10°C 8.17 0.019
71 3/15/2013 10 10°C 8.84 0.003
72 3/15/2013 10 10°C 11.96 0.003
73 3/19/2013 6 10°C 11.36 0.015
74 3/19/2013 7 10°C 12.61 0.012
75 3/19/2013 6 20°C 8.4 0.006 Dichloramine Experiment
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Experiment Date Virus Stock Stock Age (months) Target No Actual No % of Target
1 12/17/2011 5 9 4.50E+05 7.76E+05 172.55%
2 12/17/2011 5 9 4.50E+05 9.65E+04 21.44%
3 1/26/2012 5 10.27 4.50E+05 3.18E+05 70.59%
4 2/2/2012 5 10.48 4.50E+05
5 2/9/2012 5 10.7 4.00E+05 2.24E+05 55.88%
6 3/12/2012 Unknown 5.88E+05
7 7/2/2012 6 2.73 1.55E+05 2.82E+04 18.19%
8 7/9/2012 6 3 1.55E+05 3.51E+05 225.82%
9 7/25/2012 6 3.5 1.55E+05 1.99E+05 128.07%
10 7/30/2012 6 3.66 1.55E+05 9.18E+04 59.11%
11 8/14/2012 6 4.13 1.38E+05 1.58E+04 11.42%
12 8/16/2012 6 4.2 1.55E+05 6.59E+04 42.44%
13 9/21/2012 6 5.37 1.38E+05 9.53E+04 69.05%
14 9/28/2012 6 5.6 1.38E+05 1.06E+05 76.73%
15 10/5/2012 6 5.67 1.55E+05 4.44E+04 28.57%
16 10/12/2012 8 1.13 1.00E+05 6.00E+03 6.00%
17 10/15/2012 8 1.23 1.00E+05 5.41E+04 54.12%
18 10/18/2012 8 1.33 1.13E+05 1.74E+04 15.48%
19 10/22/2012 8 1.47 1.13E+05 2.26E+04 20.13%
20 10/24/2012 8 1.53 1.13E+05 2.35E+04 20.92%
21 11/27/2012 8 2.63 1.13E+05 1.65E+04 14.64%
22 11/27/2012 Unpurified Stock 6 7.50E+05 8.12E+05 108.24%
23 12/6/2012 Unpurified Stock 6.3 5.00E+05 3.04E+05 60.75%
24 12/18/2012 Unpurified Stock 6.68 4.08E+05 3.42E+05 83.88%
25 12/24/2012 9 0.68 2.55E+05 5.18E+05 203.00%
26 12/24/2012 9 0.68 2.55E+05 2.00E+05 78.43%
27 12/29/2012 9 0.71 1.28E+05 3.53E+04 27.57%
28 12/29/2012 9 0.94 1.28E+05 2.47E+04 19.30%
29 1/1/2013 9 1.13 2.17E+05 2.42E+05 111.41%
30 1/8/2013 9 1.13 2.17E+05 2.86E+05 131.91%
31 1/8/2013 9 1.39 2.55E+05 2.55E+05 100.12%
32 1/15/2013 9 1.39 2.55E+05 1.42E+06 555.95%
33 1/15/2013 9 1.42 2.55E+05 1.89E+05 74.05%
34 1/16/2013 9 1.42 2.55E+05 1.64E+05 64.13%
35 1/16/2013 9 1.55 2.55E+05 1.52E+05 59.75%
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Experiment Date Virus Stock Stock Age (months) Target No Actual No % of Target
36 1/20/2013 9 1.55 2.55E+05 6.71E+05 262.98%
37 1/20/2013 9 1.61 2.55E+05 4.94E+05 193.77%
38 1/22/2013 9 3.26 2.55E+05 1.11E+05 43.37%
39 1/22/2013 10 0.52 1.77E+06 9.65E+03 0.55%
40 1/28/2013 10 0.71 1.77E+06 9.76E+04 5.52%
41 1/28/2013 10 0.71 1.77E+06 3.32E+05 18.74%
42 1/29/2013 10 0.74 1.77E+06 6.12E+04 3.46%
43 1/29/2013 10 0.74 1.77E+06 6.47E+04 3.66%
44 2/4/2013 10 0.97 1.77E+06 1.11E+05 6.25%
45 2/4/2013 10 0.97 1.77E+06 7.65E+04 4.32%
46 2/6/2013 10 1 1.77E+06 7.53E+04 4.25%
47 2/6/2013 10 1 1.77E+06 1.12E+05 6.31%
48 2/10/2013 10 1.16 1.77E+06 1.27E+06 71.78%
49 2/10/2013 10 1.16 1.77E+06 1.79E+05 10.10%
50 2/10/2013 10 1.16 1.77E+06 3.65E+05 20.60%
51 2/10/2013 10 1.16 1.77E+06 2.59E+05 14.62%
52 2/12/2013 10 1.19 8.85E+05 6.24E+04 7.05%
53 2/12/2013 10 1.19 8.85E+05 3.29E+04 3.72%
54 2/13/2013 10 1.23 8.85E+05 2.58E+05 29.15%
55 2/13/2013 10 1.23 8.85E+05 8.59E+04 9.71%
56 2/14/2013 10 1.26 8.85E+05 1.45E+05 16.38%
57 2/18/2013 10 1.35 1.77E+06 9.18E+05 51.86%
58 2/18/2013 10 1.35 1.77E+06 6.00E+05 33.90%
59 2/20/2013 10 1.45 8.85E+05 4.71E+04 5.32%
60 2/20/2013 10 1.45 8.85E+05 4.00E+03 0.45%
61 2/21/2013 10 1.48 8.85E+05 1.45E+05 16.38%
62 2/26/2013 10 1.54 1.77E+06 2.42E+05 13.69%
63 3/1/2013 10 1.81 1.77E+06 4.35E+05 24.59%
64 3/6/2013 10 2 1.77E+06 2.12E+05 11.96%
65 3/11/2013 10 2.17 1.77E+06 3.53E+05 19.94%
66 3/11/2013 10 2.17 1.77E+06 8.12E+05 45.86%
67 3/13/2013 10 2.23 1.77E+06 8.47E+04 4.79%
68 3/13/2013 10 2.23 1.77E+06
69 3/14/2013 10 2.27 1.77E+06 1.79E+05 10.14%
70 3/14/2013 10_2 2.47 5.76E+05 4.59E+05 79.66%
71 3/15/2013 10_2 2.5 5.76E+05 1.61E+05 27.93%
72 3/15/2013 10_2 2.5 5.76E+05 4.94E+05 85.78%
73 3/19/2013 10_2 2.62 5.76E+05 8.24E+05 142.97%
74 3/19/2013 10_2 2.62 5.76E+05 7.76E+05 134.80%
75 3/19/2013 10_2 2.62 5.76E+05 5.65E+05 98.04%
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Appendix C: Effect of Monochloramine Concentration on CVB5 Inactivation 


















Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
62 3/1/2013 6 10°C 8.43 0.022
68 3/14/2013 6 10°C 8.95 0.015
69 3/14/2013 6 10°C 8.17 0.019


















CVB5 Survival Ratio vs. CT at pH 6, 10°C 





















Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
15 10/5/2012 6 20°C 9.29 0.066
18 10/18/2012 6 20°C 8.06 0.076
49 2/10/2013 6 20°C 7.13 0.078
50 2/10/2013 6 20°C 3.75 0.071

























Experimental Summary for pH 6, 30°C 	  

















Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
11 8/14/2012 6 30°C 8.29 0.148
13 9/21/2012 6 30°C 8.8 0.208
38 1/22/2013 6 30°C 6.3 0.147
39 1/22/2013 6 30°C 7.89 0.153


















CVB5 Inactivation at pH 6, 30° C 
5.00	  mg/L	  8.29	  mg/L	  6.30	  mg/L	  7.89	  mg/L	  8.80	  mg/L	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Experimental Summary for pH 6.5 	  
	  
  
Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
14 9/28/2012 6.5 20°C 8.29 0.065
17 10/15/2012 6.5 20°C 10.8 0.042
19 10/22/2012 6.5 10°C 11.5 0.023
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Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
55 2/14/2013 7 10°C 4.77 0.012
56 2/18/2013 7 10°C 6.03 0.064
66 3/13/2013 7 10°C 8.67 0.013
67 3/13/2013 7 10°C 9.1 0.016


















CVB5 Inactivation at pH 7, 10° C 
 4.8	  mg/L	  8.7	  mg/L	  9.1	  mg/L	  12.61	  mg/L	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Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
20 10/24/2012 7 20°C 6.55 0.083
48 2/10/2013 7 20°C 6.23 0.061
51 2/10/2013 7 20°C 4.47 0.065














Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
12 8/16/2012 7 30°C 7.83 0.38
36 1/20/2013 7 30°C 7.4 0.218
37 1/20/2013 7 30°C 4.53 0.223
43 1/29/2013 7 30°C 6.51 0.182
46 2/6/2013 7 30°C 9.33 0.045

















































Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
53 2/13/2013 8 10°C 7.54 0.009
61 2/21/2013 8 10°C 6.77 0.013
62 2/26/2013 8 10°C 8.87 0.007
64 3/6/2013 8 10°C 9.08 0.007


















CVB5 Inactivation at pH 8, 10°C  













Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
5 2/9/2012 8 20°C 8.64 0.017
25 12/24/2012 8 20°C 9.97 0.019
27 12/29/2012 8 20°C 12.06 0.025
30 1/8/2013 8 20°C 12.05 0.018


















CVB5 Inactivation at pH 8, 20°C  
5.04	  mg/L	  8.64	  mg/L	  9.97	  mg/L	  12.05	  mg/L	  12.06	  mg/L	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Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
1 12/17/2011 8 30°C 7.96 0.074
34 1/16/2013 8 30°C 10.63 0.061
40 1/28/2013 8 30°C 9.74 0.06
44 2/4/2013 8 30°C 5.11 0.097


















CVB5 Inactivation at pH 8, 30°C  7.96	  mg/L	  10.63	  mg/L	  5.03	  mg/L	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Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
54 2/13/2013 10 10°C 7.54 0.004
64 3/11/2013 10 10°C 13.5 0.004
70 3/15/2013 10 10°C 8.84 0.003



















CVB5 Inactivation at pH 10, 10°C 
7.54	  mg/L	  13.50	  mg/L	  8.84	  mg/L	  11.96	  mg/L	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Experiment Date pH Temperature[NH2Cl] (mg/L as Cl2) k (L/(mg*min))
26 12/24/2012 10 20°C 10.54 0.011
28 12/29/2012 10 20°C 10.61 0.013
29 1/1/2012 10 20°C 21.46 0.016
31 1/8/2013 10 20°C 7.77 0.012


















CVB5 Inactivation at pH 10, 20°C 
 11.10	  mg/L	  7.77	  mg/L	  21.46	  mg/L	  10.61	  mg/L	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Experiment Date pH Temperature [NH2Cl] (mg/L as Cl2) k (L/(mg*min))
2 12/17/2011 10 30°C 7.64 0.08
33 1/15/2013 10 30°C 7.03 0.041
35 1/16/2013 10 30°C 7.58 0.043


















CVB5 Inactivation at pH 10, 30°C 7.58	  mg/L	  7.03	  mg/L	  7.64	  mg/L	  10.77	  mg/L	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CVB5 Inactivation at pH 10 
10C,	  7.54	  mg/L	  10C,	  8.84	  mg/L	  10C,	  11.96	  mg/L	  10C,	  13.50	  mg/L	  20C,	  7.77	  mg/L	  20C,	  10.54	  mg/L	  20C,	  10.61	  mg/L	  20C,	  11.10	  mg/L	  20C,	  21.46	  mg/L	  30C,	  7.03	  mg/L	  30C,	  7.58	  mg/L	  30C,	  7.64	  mg/L	  30C,	  10.77	  mg/L	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Age of Stock (months) 




















Age of Stock (months) 




























Age of Stock (months) 
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Age of Stock (months) 
CVB5 Stock 10 Concentration over Time 
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Appendix F: Transmission Electron Microscopy Images  
 
	  
Figure 12. TEM image of unpurified CVB5 stock 
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Appendix G: Experimental Data  	  








Time CT 0 -1 -2 -3 -4 -5 Count N/No log(N/No)
0 0.0 138+ 66 14 776470.588 1 0.00
0.72 5.7 tntc x 56 658823.529 0.84848485 -0.07
1.68 13.4 tntc tntc 73 11 85882.3529 0.11060606 -0.96
3.58 28.5 tntc 164 62 46117.6471 0.05939394 -1.23
6.52 51.9 tntc 87 17 10235.2941 0.01318182 -1.88
10.47 83.3 tntc 99 15 1164.70588 0.0015 -2.82
15.62 124.3 108 11 127.058824 0.00016364 -3.79
18.7 148.8 8 0



















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp 29.5  Final temp 29.7 
Initial pH 9.58 Final pH 9.60 
Initial abs. 0.164 Final abs. 0.161  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.161 10 7.65 
0 0.173 10 8.22 
1.58 0.166 10 7.89 
6.75 0.167 10 7.93 
13.13 0.173 10 8.22 
28.45 0.165 10 7.84 
Average Concentration [NH2Cl] mg/L as Cl2  7.96 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No log(N/No)
No 0 0.0 82 x 96470.588 1 0
1 0.52 4.0 tntc 78 19 157647.06 1.63414634 0.21329095
2 2.3 17.6 tntc 48 11 56470.588 0.58536585 -0.2325726
3 4.22 32.2 171 53 5 4123.5294 0.0427439 -1.3691258
4 11.77 89.9 14 0 0
5 20.22 154.5 0 0 0 0
6 31.32 239.3 0 0 0 0
7 51.33 392.2 0 0 0 0
8 59.5 454.7 0 0 0


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp 29.5  Final temp 29.7 
Initial pH 9.58 Final pH 9.60 
Initial abs. 0.159 Final abs. 0.156  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0.00 0.159 10 7.55 
0.00 0.167 10 7.93 
2.00 0.161 10 7.65 
7.27 0.168 10 7.98 
28.42 0.159 10 7.55 
81.00 0.156 10 7.41 
84.00 0.156 10 7.41 
Average Concentration [NH2Cl] mg/L as Cl2  7.64 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 27 2 0 317647.059 1 0
1 1.4 11.9 tntc 24 5 1 282352.941 0.88888889 -0.0511525
2 5.07 43.1 tntc 45 0 529411.765 1.66666667 0.22184875
3 10.12 85.9 tntc 20 1 235294.118 0.74074074 -0.1303338
4 15.7 133.3 tntc 14 0
5 31.17 264.7 tntc 56 8 0 65882.3529 0.20740741 -0.6831757
6 61.15 519.3 tntc tntc 36 42352.9412 0.13333333 -0.8750613
7 119.45 1014.3 tntc tntc 34 4000 0.01259259 -1.8998848
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp 5.1  Final temp 5.2 
Initial pH 8.05 Final pH 8.1 
Initial abs. 0.178 Final abs. 0.175  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.178 10 8.46 
5.85 0.180 10 8.55 
11.08 0.177 10 8.41 
16.7 0.181 10 8.60 
33.7 0.180 10 8.55 
62.02 0.182 10 8.65 
121.23 0.177 10 8.41 
206.3 0.175 10 8.31 
Average Concentration [NH2Cl] mg/L as Cl2  8.49 
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Inactivation of CVB5 with Monochloramine, Experiment #4 
Date: 02/02/2012 






Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No* Log(N/No*)
No 0 0.0 x 0 0 0
1 1 11.3 28 9 0 0 32941.176
2 5.167 58.2 83 13 0 97647.059
3 10.5 118.2 tntc 7 0
4 15 168.9 72 8 0 84705.882
5 29.95 337.2 191+ 43 6 1 50588.235
6 61.1 687.9 tntc tntc 180+ 9
7 122.21 1376.0 tntc tntc 32 3764.7059
8 178.61 2011.0 x x
Initial Conditions Final Conditions 
Initial temp 5.0 Final temp 5.2 
Initial pH 9.0 Final pH 8.7 
Initial abs. 0.238 Final abs. 0.240  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.238 10 11.31 
9.6 0.237 10 11.26 
16 0.234 10 11.12 
31.52 0.241 10 11.45 
64.83 0.232 10 11.02 
180.22 0.240 10 11.40 
Average Concentration [NH2Cl] mg/L as Cl2  11.26 
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Inactivation of CVB5 with Monochloramine, Experiment #5 
Date: 02/09/2012 






Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No log(N/No)
No 0 0.0 19 1 1 223529.412 1 0
1* 1.067 9.2 23 7 0 27058.8235 0.12105263 -0.9170258
2 5.97 51.6 31 1 0 36470.5882 0.16315789 -0.7873919
3 10.08 87.1 28 4 1 32941.1765 0.14736842 -0.8315956
4 15.11 130.6 97 14 1 0 11411.7647 0.05105263 -1.2919819
5 28.75 248.4 tntc tntc 18 5 2117.64706 0.00947368 -2.0234811
6 59.73 516.1 37 8 1 0 43.5294118 0.00019474 -3.7105519
7 92.25 797.1 2 0 0


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.2 Final temp (°C) 20.2 
Initial pH 8.1 Final pH 8.14 
Initial abs. 0.179 Final abs. 0.178  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.179 10 8.50 
4.35 0.188 10 8.93 
8.50 0.186 10 8.84 
16.03 0.183 10 8.69 
26.25 0.179 10 8.50 
61.55 0.181 10 8.60 
95.25 0.181 10 8.60 
122.35 0.178 10 8.46 
Average Concentration [NH2Cl] mg/L as Cl2  8.64 
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Inactivation of CVB5 with Monochloramine, Experiment #6 
Date: 03/12/2012 








Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No log (N/No)
No 0 0.0 50 4 588235.294 1 0
1 1 7.7 tntc 90 10 105882.353 0.18 -0.744727
2 5.05 38.8 tntc 49 6 57647.0588 0.098 -1.008774
3 10.2 78.4 tntc 45 11 5294.11765 0.009 -2.045757
4 15.03 115.6 71 16 0 1358.82353 0.00231 -2.636388
5 29.37 225.8 17 0 20 0.000034 -4.468521
6 59.92 460.7 0 2



















CVB5 Survival Ratio vs. CT	

Initial Conditions Final Conditions 
Initial temp  (°C) 20.3 Final temp (°C) 20.4 
Initial pH 7.97 Final pH 8.24 
Initial abs. 0.163 Final abs. 0.160  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.163 10 7.74 
3.45 0.163 10 7.74 
9.15 0.160 10 7.60 
19.35 0.164 10 7.79 
38.75 0.164 10 7.79 
59.32 0.159 10 7.55 
102.88 0.160 10 7.60 
Average Concentration [NH2Cl] mg/L as Cl2  7.69 
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Inactivation of CVB5 with Monochloramine, Experiment #7 
Date: 07/02/2012 
Comments: Formaldehyde Experiment (R1: Formaldehyde and CVB5; R2: Monochloramine, 








Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No log(N/No)
No 0 0.0 24 2 0 28235.2941 1 0
R1 final 21.32 233.0 176 29 2 27411.7647 0.97083333 -0.0128553
1 1.27 13.9 196 48 3 0 3976.47059 0.14083333 -0.8512945
2 2.02 22.1 tntc 184 13 0 0 2164.70588 0.07666667 -1.1153934
3 5.27 57.6 28 13 0 0 32.9411765 0.00116667 -2.9330532
4 7.43 81.2 6 0 0 0
5 10.05 109.8 0 0 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 25.0 Final temp (°C) 25.2 
Initial pH R1 7.30 Final pH R1 7.41 
Initial pH R2 7.26 Final pH R2 7.50 
Initial abs. 0.229 Final abs. 0.224  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.229 10 10.88 
3.48 0.221 10 10.50 
5.95 0.244 10 11.59 
8.95 0.226 10 10.74 
15.78 0.236 10 11.21 
23.3 0.224 10 10.64 
Average Concentration [NH2Cl] mg/L as Cl2  10.93 
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Inactivation of CVB5 with Monochloramine, Experiment #8 
Date: 07/09/2012 







Sample Time (min) CT 0 -1 -2 -3 -4 No N/No log(N/No)
No 0 0.0 tntc 226 37 350588.235 1 0
1* 1.18 10.0 tntc 112 17 1 16588.2353 0.04731544 -1.32499715
2 2.05 17.4 267 29 3 0 3276.47059 0.00934564 -2.02939106
3 3.08 26.2 141 9 3 1658.82353 0.00473154 -2.32499715
4 5.13 43.7 131 32 3 0 265.294118 0.00075671 -3.12106972
5 7.47 63.6 29 5 0 34.1176471 9.7315E-05 -4.01181827
6 10.08 85.8 2 0 0



















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 25.0 Final temp (°C) 25.1 
Initial pH 7.30 Final pH 7.50 
Initial abs. 0.182 Final abs. 0.184  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.229 10 8.65 
0 0.221 10 8.41 
1.65 0.244 10 8.69 
6.05 0.226 10 8.41 
9.72 0.236 10 8.46 
13.05 0.224 10 8.22 
19.03 0.184 10 8.74 
Average Concentration [NH2Cl] mg/L as Cl2  8.51 
90	  	  








Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 tntc 169 x 198823.5 1 0
R1 15.9 161.1 167 22 227647.1 1.1449704 0.058794265
1 1 10.1 tntc 138 12 0 16235.29 0.0816568 -1.08800762
2 2.03 20.6 144 18 0 1905.882 0.0095858 -2.01837169
3 3.23 32.7 64 0 0 752.9412 0.003787 -2.42170673
4 5.02 50.9 42 11 1 0 49.41176 0.0002485 -3.60463741
5 7.55 76.5 15 7 0 17.64706 8.876E-05 -4.05179545
6 10.33 104.7 3 0




















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 25.0 Final temp (°C) 25.1 
Initial pH R1 7.27 Final pH R1 7.25 
Initial pH R2 7.24 Final pH R2 7.35 
Initial abs. 0.211 Final abs. 0.218  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.211 10 10.02 
0 0.212 10 10.07 
2.75 0.214 10 10.17 
6.08 0.214 10 10.17 
9.02 0.217 10 10.31 
12.1 0.207 10 9.83 
14.13 0.218 10 10.36 
Average Concentration [NH2Cl] mg/L as Cl2  10.13 
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Inactivation of CVB5 with Monochloramine, Experiment #10 
Date: 07/30/2012 
Comments: Formaldehyde Experiment (R1: Formaldehyde and CVB5; R2: Monochloramine, 





Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No log (N/No)
R1 No 0 0.0 tntc 78 13 0 91764.7059 1 0
R1 13.42 117.1 199 64 7 49352.9412 0.53782051 -0.2693626
1 1.02 0.0 tntc 84 15 3 13764.7059 0.15 -0.8239087
2 2.08 18.1 tntc 141 47 0 3594.11765 0.03916667 -1.4070834
3 3.4 29.7 tntc 137 27 2 2394.11765 0.02608974 -1.5835302
4 5.32 46.4 tntc 60 10 0 705.882353 0.00769231 -2.1139434
5 7.72 67.3 111 40 0 300.588235 0.00327564 -2.4847037

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 25.0 Final temp (°C) 25.1 
Initial pH R1 7.24 Final pH R1 7.44 
Initial pH R2 7.23 Final pH R2 7.38 
Initial abs. 0.200 Final abs. 0.176  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.200 10 9.50 
2.55 0.180 10 8.55 
4.97 0.179 10 8.50 
7.05 0.183 10 8.69 
11.65 0.176 10 8.36 
Average Concentration [NH2Cl] mg/L as Cl2  8.72 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 118 15 0 15764.7059 1 0
1 1.25 10.4 103 9 2 0 1211.76471 0.07686567 -1.1142676
2 3.17 26.3 124 17 1 0 172.941176 0.01097015 -1.9597875
3 5.27 43.7 38 4 0 0 44.7058824 0.00283582 -2.5473212
4 7.28 60.3 11 0 0 0
5 10.48 86.8 3 2 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 29.9 Final temp (°C) 30 
Initial pH 6.00 Final pH 6.14 
Initial abs. 0.175 Final abs. 0.170  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.175 10 8.31 
0.78 0.171 10 8.12 
3.43 0.172 10 8.17 
5.53 0.173 10 8.22 
7.52 0.180 10 8.55 
10.92 0.180 10 8.55 
18.47 0.170 10 8.08 
Average Concentration [NH2Cl] mg/L as Cl2  8.29 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 174+ 56 3 65882.3529 1 0
1 0.4 3.1 109+ 104 31 0 0 2435.29412 0.03696429 -1.4322177
2 1.45 11.4 82 47 5 0 324.705882 0.00492857 -2.3072789
3 3 23.5 16 6 1 0 18.8235294 0.00028571 -3.544068
4 4.67 36.6 1 0 0
5 5.47 42.8 0 1 0


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.1 Final temp (°C) 29.9 
Initial pH 6.98 Final pH 7.03 
Initial abs. 0.130 Final abs. 0.170  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.130 10 6.18 
0.78 0.168 10 7.98 
3.43 0.166 10 7.89 
5.53 0.173 10 8.22 
7.52 0.168 10 7.98 
10.92 0.179 10 8.50 
18.47 0.10 10 8.08 
Average Concentration [NH2Cl] mg/L as Cl2  7.83 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 81 9 95294.1176 1 0
1 0.45 4.0 tntc 214 36 5 33764.7059 0.35432099 -0.4506031
2 1.3 11.4 tntc tntc 78 4 9176.47059 0.0962963 -1.0163904
3 2.77 24.4 tntc 52 7 0 611.764706 0.00641975 -2.1924817
4 4.3 37.8 x 3 0 0
5 7.47 65.7 1 0 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.0 Final temp (°C) 29.9 
Initial pH 6.03 Final pH 6.23 
Initial abs. 0.165 Final abs. 0.185  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.130 10 8.79 
0 0.168 10 7.84 
1.45 0.166 10 9.07 
3.75 0.173 10 9.50 
8.88 0.168 10 8.79 
Average Concentration [NH2Cl] mg/L as Cl2  8.80 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 90 4 105882.353 1 0
1 0.98 8.1 tntc 149 17 1 18764.7059 0.17722222 -0.7514818
2 3.28 27.2 tntc 97 8 0 11411.7647 0.10777778 -0.9674708
3 5.17 42.9 tntc 187 41 5 3511.76471 0.03316667 -1.4792982
4 10.08 83.6 201 89 11 0 641.764706 0.00606111 -2.2174478
5 15.22 126.2 28 13 0 32.9411765 0.00031111 -3.5070845
6 20.67 171.3 9 2 0
































CVB5 Survival Ratio vs. CT	

Initial Conditions Final Conditions 
Initial temp  (°C) 19.9 Final temp (°C) 19.9 
Initial pH 6.54 Final pH 6.57 
Initial abs. 0.160 Final abs. 0.178  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.160 10 7.60 
1.97 0.171 10 8.12 
4.42 0.168 10 7.98 
6.80 0.164 10 7.79 
10.37 0.199 10 9.45 
14.92 0.175 10 8.31 
19.52 0.181 10 8.60 
26.87 0.178 10 8.46 
Average Concentration [NH2Cl] mg/L as Cl2  8.29 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 164 59 8 44352.9412 1 0
1 0.97 9.0 tntc 100 14 1 13404.8257 0.30223082 -0.5196613
2 3.93 36.5 56 4 6588.23529 0.14854111 -0.8281533
3 5.6 52.0 tntc 61 23 2 1711.76471 0.03859416 -1.4134784
4 7.68 71.3 120 37 0 0 288.235294 0.00649867 -2.1871753
5 10.38 96.4 10 5 3
6 15.32 142.3 5 0 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.1 Final temp (°C) 19.6 
Initial pH 6.05 Final pH 6.16 
Initial abs. 0.198 Final abs. 0.185  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.198 10 9.41 
1.85 0.195 10 9.26 
5.87 0.201 10 9.55 
9.05 0.204 10 9.69 
13.02 0.191 10 9.07 
15.02 0.208 10 9.88 
17.27 0.182 10 8.65 
19.9 0.185 10 8.79 
Average Concentration [NH2Cl] mg/L as Cl2  9.29 
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Inactivation of CVB5 with Monochloramine, Experiment #16 
Date: 10/12/2012 











Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 51 6 0 0 60000 1 0
1 1.05 10.4 2 0 0 0
2 3.38 33.4 0 0 2 2
3 5.22 51.6 4 0 1 0
4 10.35 102.3 4 0 1 0
5 15.28 151.0 16 5 0 0 18.82353 0.000314 -3.50345


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.7 Final temp (°C) 20.2 
Initial pH 7.04 Final pH 7.26 
Initial abs. 0.205 Final abs. 0.200  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.205 10 9.74 
0.092 0.205 10 9.74 
3.7 0.208 10 9.88 
7.05 0.212 10 10.07 
11.07 0.193 10 9.17 
15.23 0.189 10 8.98 
25.25 0.200 10 9.50 
Average Concentration [NH2Cl] mg/L as Cl2  9.58 
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Inactivation of CVB5 with Monochloramine, Experiment #17 
Date: 10/15/2012 









Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 tntc 46 6 0 0 54117.6471 1 0
1 1.17 12.6 x 9 1 0
2 3.07 33.2 183 21 1 0 23117.6471 0.42717391 -0.3693953
3 5.3 57.2 30 5 1 0 3529.41176 0.06521739 -1.1856366
4 10.35 111.8 3 0 0
5 15.03 162.3 0 0 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.1 Final temp (°C) 20.3 
Initial pH 6.51 Final pH 6.63 
Initial abs. 0.230 Final abs. 0.238  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.230 10 10.93 
0 0.231 10 10.97 
2.42 0.240 10 11.40 
5.05 0.220 10 10.45 
7.30 0.233 10 11.07 
8.93 0.230 10 10.93 
13.45 0.220 10 10.45 
18.35 0.204 10 9.69 
21.07 0.238 10 11.31 
Average Concentration [NH2Cl] mg/L as Cl2  10.80 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 148 12 0 0 0 17411.7647 1 0
1 1.15 9.3 95 10 1 11176.4706 0.64189189 -0.1925381
2 3.02 24.4 tntc 40 4 0 4705.88235 0.27027027 -0.5682017
3 5.48 44.2 186 52 8 0 415.294118 0.02385135 -1.622487
4 7.55 60.9 86 29 2 221.176471 0.0127027 -1.8961039
5 10.33 83.3 23 4 27.0588235 0.00155405 -2.8085339

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.6 Final temp (°C) 19.8 
Initial pH 6.02 Final pH 6.25 
Initial abs. 0.179 Final abs. 0.172  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.179 10 8.50 
0 0.184 10 8.74 
1.40 0.163 10 7.74 
3.40 0.167 10 7.93 
6.10 0.165 10 7.84 
8.43 0.159 10 7.55 
10.77 0.169 10 8.03 
12.7 0.172 10 8.17 
Average Concentration [NH2Cl] mg/L as Cl2  8.06 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 135 25 2 22647.0588 1 0
1 0.85 9.8 81 14 1 9529.41176 0.42077922 -0.3759457
2 5.2 59.8 tntc 53 6 1 6235.29412 0.27532468 -0.5601549
3 10.4 119.6 tntc 68 15 1 x 1282.35294 0.05662338 -1.2470042
4 14.93 171.6 tntc 41 5 0 482.352941 0.0212987 -1.6716469
5 30.22 347.4 3 0 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.2 Final temp (°C) 10.5 
Initial pH 6.6 Final pH 6.76 
Initial abs. 0.240 Final abs. 0.252  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.240 10 11.40 
0 0.251 10 11.92 
2.07 0.260 10 12.35 
4.98 0.241 10 11.45 
10.13 0.237 10 11.26 
14.7 0.242 10 11.50 
28.9 0.226 10 10.74 
34.8 0.229 10 10.88 
43.48 0.252 10 11.97 
Average Concentration [NH2Cl] mg/L as Cl2  11.50 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0 tntc 20 3 0 23529.4118 1 0
1 1.37 8.9721751 51 5 0 6000 0.255 -0.5934598
2 3 19.647099 27 6 0 3176.47059 0.135 -0.8696662
3 5.07 33.203597 tntc 88 16 0 1458.82353 0.062 -1.2076083
4 9.78 64.049542 94 15 x 0 143.529412 0.0061 -2.2146702
5 15.8 103.47472 3 1 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.2 Final temp (°C) 20.3 
Initial pH 7.00 Final pH 7.02 
Initial abs. 0.135 Final abs. 0.136  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.135 10 6.41 
0.98 0.136 10 6.46 
4.83 0.145 10 6.89 
6.13 0.141 10 6.70 
11.08 0.139 10 6.60 
16.7 0.133 10 6.32 
20.57 0.136 10 6.46 
Average Concentration [NH2Cl] mg/L as Cl2  6.55 
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Inactivation of CVB5 with Monochloramine, Experiment #21 
Date: 11/27/2012 








Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 130 15 1 16470.5882 1 0
1 0.52 5.7 tntc 69 12 2 8117.64706 0.49285714 -0.3072789
2 1 11.0 tntc tntc 51 6 6000 0.36428571 -0.4385579
3 1.63 18.0 tntc tntc 45 0 5294.11765 0.32142857 -0.4929155
4 2.18 24.1 tntc 263 25 3017.64706 0.18321429 -0.7370407
5 3.33 36.7 tntc 119 21 1935.29412 0.1175 -0.9299621
6 5.47 60.4 246+ 92 1082.35294 0.06571429 -1.1823402
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.1 Final temp (°C) 19.9 
Initial pH 7.93 Final pH 8.00 
Initial abs. 0.232 Final abs. 0.242  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.232 10 11.02 
0 0.233 10 11.07 
0.27 0.227 10 10.78 
0.85 0.234 10 11.12 
4.6 0.231 10 10.97 
5.9 0.227 10 10.78 
7.35 0.242 10 11.50 
Average Concentration [NH2Cl] mg/L as Cl2  11.03 
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Inactivation of CVB5 with Monochloramine, Experiment #22 
Date: 11/27/2012 
Comments: Unpurified CVB5 stock experiment. Sample 2* is an outlier data point. Not used; 







Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc tntc 69 811764.706 1 0
1 0.53 6.1 tntc tntc 146 42 332941.176 0.41014493 -0.3870627
2* 1.1 12.6 tntc tntc tntc 74 870588.235 1.07246377 0.03038263
3 1.7 19.5 tntc tntc tntc 204 240000 0.29565217 -0.5292189
4 2.17 24.9 tntc tntc tntc
5 3.47 39.8 tntc tntc tntc
6 4.9 56.2 tntc tntc
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.9 Final temp (°C) 19.9 
Initial pH 8.00 Final pH 7.84 
Initial abs. 0.264 Final abs. 0.216  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.263 10 12.49 
0 0.260 10 12.35 
0.23 0.223 10 10.59 
0.83 0.250 10 11.88 
4.6 0.243 10 11.54 
5.63 0.263 10 12.49 
7.53 0.212 10 10.07 
7.77 0.216 10 10.26 
Average Concentration [NH2Cl] mg/L as Cl2  11.46 
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Inactivation of CVB5 with Monochloramine, Experiment #23 
Date: 12/06/2012 







Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 tntc 25 4 303766.707 1 0
1 2.2 23.2 tntc 77 17 0 145294.118 0.47830824 -0.3202921
2 5.05 53.2 tntc tntc 36 2 42352.9412 0.13942588 -0.8556566
3 10.07 106.1 tntc tntc 90 14 13529.4118 0.04453882 -1.3512613
4 15.48 163.2 tntc 230 39 11 3647.05882 0.01200612 -1.9205974


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.1 Final temp (°C) 20.2 
Initial pH 8.20 Final pH 8 
Initial abs. 0.236 Final abs. 0.201  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.240 10 11.40 
0 0.236 10 11.21 
3.13 0.208 10 9.88 
4.87 0.212 10 10.07 
7.35 0.219 10 10.40 
11.17 0.237 10 11.26 
32.67 0.201 10 9.55 
Average Concentration [NH2Cl] mg/L as Cl2  10.54 
105	  	  
Inactivation of CVB5 with Monochloramine, Experiment #24 
Date: 12/18/2012 







Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 105 18 0 342241.441 1 0
1 2.1 24.8 120 11 0 141176.471 0.41250548 -0.3845703
2 5.05 59.7 x x x x
3 10.08 119.2 x x x
4 14.82 175.3 x x x x
5 25.9 306.4 46 15 115.294118 0.00033688 -3.4725254


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.9 Final temp (°C) 20.0 
Initial pH 8.18 Final pH 8.16 
Initial abs. 0.254 Final abs. 0.249  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.254 10 12.07 
0.52 0.253 10 12.02 
1.90 0.259 10 12.30 
3.97 0.260 10 12.35 
7.02 0.261 10 12.40 
13.35 0.254 10 12.07 
21.10 0.255 10 12.11 
28.82 0.251 10 11.92 
36.38 0.249 10 11.83 
Average Concentration [NH2Cl] mg/L as Cl2  12.12 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 44 5 1 517647.059 1 0
1 2.42 24.1 28 - 0 329411.765 0.63636364 -0.1962946
2 11.33 112.9 49 16 0 57647.0588 0.11136364 -0.9532566
3 14.97 149.2 tntc 28 4 32941.1765 0.06363636 -1.1962946
4 25.33 252.5 98 48 1 0 3400 0.00656818 -2.1825548

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.5 Final temp (°C) 19.6 
Initial pH 8.05 Final pH 8.09 
Initial abs. 0.196 Final abs. 0.218  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.196 10 9.31 
1.75 0.214 10 10.17 
8.95 0.201 10 9.55 
12.90 0.216 10 10.26 
22.82 0.214 10 10.17 
30.73 0.218 10 10.36 
Average Concentration [NH2Cl] mg/L as Cl2  9.97 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 17 2 0 200000 1 0
1 2.18 23.0 10 2 1
2 11.15 117.5 102 - 2 120000 0.6 -0.2218487
3 14.83 156.3 tntc 64 4 75294.1176 0.37647059 -0.4242689
4 25.08 264.3 tntc 95 8 5 11176.4706 0.05588235 -1.2527253
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.5 Final temp (°C) 19.6 
Initial pH 9.97 Final pH 10.03 
Initial abs. 0.204 Final abs. 0.198  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.204 10 9.69 
1.48 0.250 10 11.88 
8.78 0.245 10 11.64 
12.70 0.244 10 11.59 
22.62 0.190 10 9.03 
30.62 0.198 10 9.41 
Average Concentration [NH2Cl] mg/L as Cl2  10.54 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 30 7 4 35294.1176 1 0
1 2 24.1 65 14 0 7647.05882 0.21666667 -0.6642079
2 9.68 116.7 71 4 0 0 835.294118 0.02366667 -1.6258629
3 15.05 181.5 tntc 61 8 0 717.647059 0.02033333 -1.6917914
4 26.32 317.4 x 3 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.9 Final temp (°C) 20.1 
Initial pH 7.98 Final pH 8.08 
Initial abs. 0.250 Final abs. 0.254  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.250 10 11.88 
3.57 0.260 10 12.35 
6.55 0.255 10 12.11 
16.7 0.248 10 11.78 
23.68 0.256 10 12.16 
31.52 0.254 10 12.07 
Average Concentration [NH2Cl] mg/L as Cl2  12.06 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 21 3 0 24705.8824 1 0
1 2.33 24.7 2
2 9.87 104.7 tntc 130 11 0 15294.1176 0.61904762 -0.2082759
3 14.97 158.8 tntc tntc 17 2 2000 0.08095238 -1.0917704
4 26.02 276.1 tntc 56 6 658.823529 0.02666667 -1.5740313

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.9 Final temp (°C) 20.1 
Initial pH 10.02 Final pH 9.96 
Initial abs. 0.226 Final abs. 0.228  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.226 10 10.74 
3.00 0.225 10 10.69 
6.83 0.219 10 10.40 
16.48 0.226 10 10.74 
23.48 0.216 10 10.26 
31.57 0.228 10 10.83 
Average Concentration [NH2Cl] mg/L as Cl2  10.61 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 -6 Count N/No Log(N/No)
No 0 0.0 151 26 3 2 241764.706 1 0
1 0.97 20.8 144 18 1 0 190588.235 0.78832117 -0.1032968
2 2.2 47.2 tntc 70 9 0 82352.9412 0.3406326 -0.4677138
3 4.97 106.7 tntc 181 11 0 21294.1176 0.08807786 -1.0551333
4 10.1 216.8 tntc tntc 100 8 11764.7059 0.0486618 -1.3128118
5 12.35 265.0 tntc tntc 34 4000 0.01654501 -1.7813329

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.0 Final temp (°C) 20.3 
Initial pH 10.03 Final pH 10.06 
Initial abs. 0.470 Final abs. 0.419  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.470 10 22.33 
0.17 0.480 10 22.80 
1.1 0.466 10 22.14 
3.1 0.432 10 20.52 
5.18 0.438 10 20.81 
10.28 0.506 10 24.04 
11.55 0.403 10 19.14 
14.43 0.419 10 19.90 
Average Concentration [NH2Cl] mg/L as Cl2  21.46 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 tntc 198 15 2 286235.294 1 0
1 2.18 26.3 123 19 184117.647 0.6432388 -0.1916278
2 5.6 67.5 tntc x x 2
3 9.88 119.1 tntc tntc tntc 55 64705.8824 0.22605836 -0.6457794
4 20.02 241.3 tntc tntc 76 8941.17647 0.03123716 -1.5053285


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.3 Final temp (°C) 20.3 
Initial pH 8.33 Final pH 8.41 
Initial abs. 0.264 Final abs. 0.270  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.264 10 12.54 
0.93 0.250 10 11.88 
3.85 0.218 10 10.36 
6.90 0.260 10 12.35 
11.50 0.268 10 12.73 
18.62 0.270 10 12.83 
39.52 0.230 10 10.93 
41.43 0.270 10 12.83 
Average Concentration [NH2Cl] mg/L as Cl2  12.05 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 204 23 255294.118 1 0
1 2.38 18.5 tntc tntc 21 4 247058.824 0.96774194 -0.0142404
2 5.7 44.3 tntc tntc 191 21 235882.353 0.92396313 -0.0343454
3 10.03 78.0 tntc tntc tntc 113 132941.176 0.52073733 -0.2833813
4 29.33 228.0 tntc tntc 88 10352.9412 0.040553 -1.3919771
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.3 Final temp (°C) 20.3 
Initial pH 9.96 Final pH 10.04 
Initial abs. 0.178 Final abs. 0.153  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.178 10 8.46 
1.07 0.174 10 8.27 
4.03 0.160 10 7.60 
7.05 0.156 10 7.41 
11.75 0.183 10 8.69 
25.13 0.161 10 7.65 
46.35 0.144 10 6.84 
48.61 0.153 10 7.27 
Average Concentration [NH2Cl] mg/L as Cl2  7.77 
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Inactivation of CVB5 with Monochloramine, Experiment #32 
Date: 01/15/2013 







Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 91 15 4 141764.706 1 0
1 2 15.2 x x 0
2 4.02 30.6 x x 0
3 8.58 65.2 49 x x 576.470588 0.00406639 -2.390791
4 10.83 82.3 x x x

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.3 Final temp (°C) 30.5 
Initial pH 8.01 Final pH 8.11 
Initial abs. 0.141 Final abs. 0.153  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.141 10 6.70 
1.58 0.188 10 8.93 
5.42 0.154 10 7.32 
10.30 0.162 10 7.70 
13.65 0.162 10 8.70 
19.58 0.153 10 7.27 
Average Concentration [NH2Cl] mg/L as Cl2  7.60 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 141 18 0 188823.529 1 0
1 2.28 16.0 105 10 0 123529.412 0.65420561 -0.1842857
2 4.23 29.7 tntc 39 3 45882.3529 0.24299065 -0.6144104
3 8.95 62.9 tntc tntc 26 30588.2353 0.16199377 -0.7905017
4 10.95 77.0 tntc 94 11058.8235 0.05856698 -1.2323472
5 15.48 108.8 tntc tntc 28 3294.11765 0.01744548 -1.758317

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.3 Final temp (°C) 30.5 
Initial pH 9.98 Final pH 9.94 
Initial abs. 0.148 Final abs. 0.142  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.148 10 7.03 
1.68 0.159 10 7.55 
5.62 0.138 10 6.56 
10.47 0.154 10 7.32 
13.77 0.147 10 6.98 
19.75 0.142 10 6.75 
Average Concentration [NH2Cl] mg/L as Cl2  7.03 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 139 5 1 163529.412 1 0
1 1.47 15.6 104 4 0 122352.941 0.74820144 -0.1259815
2 3.55 37.7 124 15 1 16117.6471 0.09856115 -1.0062942
3 7.27 77.3 32 4 0 3764.70588 0.02302158 -1.6378648
4 8.92 94.9 tntc 23 1 270.588235 0.00165468 -2.781287
5 10.02 106.5 188 5 0 221.176471 0.00135252 -2.868857

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.5 
Initial pH 8.22 Final pH 8.26 
Initial abs. 0.26 Final abs. 0.220  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.260 10 12.35 
0.82 0.221 10 10.50 
4.9 0.212 10 10.07 
9.25 0.192 10 9.12 
12.82 0.238 10 11.31 
15.53 0.220 10 10.45 
Average Concentration [NH2Cl] mg/L as Cl2  10.63 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 109 15 0 152352.941 1 0
1 2.73 20.7 67 1 0 78823.5294 0.51737452 -0.286195
2 4.03 30.5 tntc 42 3 49411.7647 0.32432432 -0.4890205
3 8.75 66.3 tntc 96 19 16823.5294 0.11042471 -0.9569337
4 10.18 77.2 tntc 51 15 11823.5294 0.07760618 -1.1101037
5 15.37 116.5 tntc 67 12 788.235294 0.00517375 -2.286195


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.4 
Initial pH 10.20 Final pH 10.18 
Initial abs. 0.160 Final abs. 0.150  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.160 10 7.60 
0.93 0.181 10 8.60 
5.07 0.131 10 6.22 
9.45 0.151 10 7.17 
12.83 0.158 10 7.51 
15.70 0.186 10 8.84 
18.30 0.150 10 7.13 
Average Concentration [NH2Cl] mg/L as Cl2  7.58 
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Inactivation of CVB5 with Monochloramine, Experiment #36 
Date: 01/20/2013 







Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 tntc 57 5 670588.235 1 0
1 1.15 8.5 tntc tntc 75 9 88235.2941 0.13157895 -0.8808136
2 2.08 15.4 10
3 3.12 23.1 10 5
4 4 29.6 12


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.3 Final temp (°C) 30.4 
Initial pH 7.10 Final pH 7.23 
Initial abs. 0.149 Final abs. 0.137  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.149 10 7.08 
0.17 0.148 10 7.03 
0.38 0.180 10 8.55 
3.47 0.154 10 7.32 
3.52 0.167 10 7.93 
5.83 0.137 10 6.51 
Average Concentration [NH2Cl] mg/L as Cl2  7.40 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 tntc 42 0 494117.647 1 0
1 1 4.5 tntc 141 19 194705.882 0.39404762 -0.4044513
2 2.03 9.2 tntc tntc tntc 59 69411.7647 0.14047619 -0.8523973
3 3.58 16.2 tntc tntc 91 10705.8824 0.02166667 -1.6642079
4 5.55 25.1 tntc 127 18 1805.88235 0.00365476 -2.4371409


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.1 Final temp (°C) 30.3 
Initial pH 7.10 Final pH 7.13 
Initial abs. 0.103 Final abs. 0.090  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.103 10 4.89 
0.33 0.076 10 3.61 
0.67 0.101 10 4.80 
3.97 0.094 10 4.47 
4.08 0.097 10 4.61 
6.45 0.115 10 5.46 
6.75 0.087 10 4.13 
8.87 0.090 10 4.28 
Average Concentration [NH2Cl] mg/L as Cl2  4.53 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 94 1 0 110588.235 1 0
1 1.05 6.6 tntc 83 97647.0588 0.88297872 -0.0540498
2 2.33 14.7 tntc tntc 197 21 23941.1765 0.21648936 -0.6645634
3 4.17 26.3 tntc 177 23 3 2394.11765 0.02164894 -1.6645634
4 7.23 45.6 82 8 0 96.4705882 0.00087234 -3.059314


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.2 
Initial pH 6.02 Final pH 6.12 
Initial abs. 0.131 Final abs. 0.137  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.131 10 6.22 
1.25 0.122 10 5.80 
3.17 0.130 10 6.18 
5.08 0.134 10 6.37 
6.97 0.142 10 6.75 
9.03 0.137 10 6.51 
Average Concentration [NH2Cl] mg/L as Cl2  6.30 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 67 2 2 78823.5294 1 0
1 1.05 8.3 tntc tntc 36 0 42352.9412 0.53731343 -0.2697723
2 2.08 16.4 tntc tntc 37 0 4352.94118 0.05522388 -1.2578731
3 3.07 24.2 tntc 38 6 0 447.058824 0.00567164 -2.2462912
4 5.8 45.7 41 5 1 48.2352941 0.00061194 -3.2132909


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.4 
Initial pH 6.10 Final pH 6.33 
Initial abs. 0.172 Final abs. 0.162  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.172 10 8.17 
1.23 0.181 10 8.60 
2.95 0.154 10 7.32 
4.67 0.161 10 7.65 
7.47 0.162 10 7.70 
Average Concentration [NH2Cl] mg/L as Cl2  7.89 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 83 14 0 97647.0588 1 0
1 2.33 22.7 13 3
2 4.35 42.4 26 6 0 3058.82353 0.0313253 -1.5041047
3 6.33 61.6 tntc 136 16 0 1741.17647 0.01783133 -1.7488164
4 10.12 98.6 105 26 2 214.705882 0.0021988 -2.6578152
5 15.5 151.0 15 2 17.6470588 0.00018072 -3.7429868


















CVB5 Survival Ratio vs. CT	

Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.5 
Initial pH 7.99 Final pH 8.03 
Initial abs. 0.198 Final abs. 0.196  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.198 10 9.41 
0 0.196 10 9.31 
0 0.202 10 9.60 
0.90 0.215 10 10.21 
2.55 0.198 10 9.41 
6.60 0.221 10 10.50 
14.48 0.214 10 10.17 
19.38 0.196 10 9.31 
Average Concentration [NH2Cl] mg/L as Cl2  9.74 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 284 28 4 331764.706 1 0
1 1.02 11.0 tntc 84 14 98823.5294 0.29787234 -0.5259698
2 2.27 24.4 tntc 56 4 65882.3529 0.19858156 -0.7020611
3 5.2 56.0 tntc 43 0 50588.2353 0.15248227 -0.8167807
4 8.75 94.2 tntc tntc 204 26 27294.1176 0.0822695 -1.0847611
5 12.5 134.6 tntc tntc 66 7764.70588 0.02340426 -1.6307052

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.5 Final temp (°C) 30.3 
Initial pH 10.02 Final pH 10.01 
Initial abs. 0.253 Final abs. 0.213  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.253 10 12.02 
0.57 0.234 10 11.12 
2.55 0.224 10 10.64 
5.93 0.231 10 10.97 
9.73 0.201 10 9.55 
11.98 0.231 10 10.97 
15.17 0.213 10 10.12 
Average Concentration [NH2Cl] mg/L as Cl2  10.77 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 52 2 61176.4706 1 0
1 2.3 11.5 182 18 5 0 2878.82353 0.04705769 -1.3273694
2 4.03 20.1 tntc 74 10 0 870.588235 0.01423077 -1.8467716
3 6.23 31.1 tntc 25 0 0 294.117647 0.00480769 -2.3180633
4 8.3 41.5 31 2 0 36.4705882 0.00059615 -3.2246416


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.3 Final temp (°C) 30.7 
Initial pH 6.05 Final pH 6.56 
Initial abs. 0.112 Final abs. 0.106  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.112 10 5.32 
0.60 0.102 10 4.85 
6.60 0.100 10 4.75 
8.52 0.106 10 5.04 
10.35 0.106 10 5.04 
Average Concentration [NH2Cl] mg/L as Cl2  5.00 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 52 2 61176.4706 1 0
1 2.3 11.5 182 18 5 0 2878.82353 0.04705769 -1.3273694
2 4.03 20.1 tntc 74 10 0 870.588235 0.01423077 -1.8467716
3 6.23 31.1 tntc 25 0 0 294.117647 0.00480769 -2.3180633
4 8.3 41.5 31 2 0 36.4705882 0.00059615 -3.2246416


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.7 Final temp (°C) 30.3 
Initial pH 7.23 Final pH 7.50 
Initial abs. 0.126 Final abs. 0.146  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.126 10 5.99 
2.93 0.139 10 6.60 
4.67 0.129 10 6.13 
6.35 0.145 10 6.89 
8.90 0.146 10 6.94 
Average Concentration [NH2Cl] mg/L as Cl2  6.51 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No log(N/No)
No 0 0.0 94 10 0 110588.235 1 0
1 1.1 5.6 46 0 0 54117.6471 0.4893617 -0.31037
2 2.17 11.1 155 6 0 0 18235.2941 0.16489362 -0.7827962
3 9.97 51.0 tntc 81 2 0 952.941176 0.00861702 -2.0646428
4 19.52 99.8 0 0 0 0

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.2 Final temp (°C) 30.4 
Initial pH 8.00 Final pH 7.98 
Initial abs. 0.109 Final abs. 0.113  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.109 10 5.18 
0.53 0.115 10 5.46 
2.57 0.102 10 4.85 
9.80 0.113 10 5.37 
15.67 0.104 10 4.94 
21.68 0.102 10 4.85 
27.5 0.103 10 4.89 
31.63 0.113 10 5.37 
Average Concentration [NH2Cl] mg/L as Cl2  5.11 
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Inactivation of CVB5 with Monochloramine, Experiment #45 
Date: 02/04/2013 









Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 65 0 0 76470.5882 1 0
1 1.2 6.3 28 0 0 32941.1765 0.43076923 -0.3657553
2 2.1 11.1 187 4 0 0 22000 0.13384615 -0.8733941
3 10.25 54.0 2 0 0 0
4 20.38 107.5 4 0 0 0
5 30.3 159.8 0 0
0.1 
1 












CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.3 Final temp (°C) 30.2 
Initial pH 8.01 Final pH 8.08 
Initial abs. 0.108 Final abs. 0.112  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.112 10 5.32 
1.87 0.118 10 5.61 
7.80 0.106 10 5.04 
11.53 0.112 10 5.32 
15.67 0.111 10 5.27 
21.33 0.110 10 5.23 
28.50 0.108 10 5.13 
Average Concentration [NH2Cl] mg/L as Cl2  5.27 
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Inactivation of CVB5 with Monochloramine, Experiment #46 
Date: 02/06/2013 










Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 64 6 0 75294.1176 1 0
1* 0.55 5.6 21 x 0 24705.8824 0.328125 -0.4839607
2 1 11.0 tntc 123 11 0 14470.5882 0.1921875 -0.7162749
3 2.03 50.4 tntc tntc 25 0 2941.17647 0.0390625 -1.40824
4 3.52 98.6 tntc 64 3 0 752.941176 0.01 -2

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.0 Final temp (°C) 30.1 
Initial pH 7.04 Final pH 7.16 
Initial abs. 0.200 Final abs. 0.192  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.200 10 9.50 
0.22 0.203 10 9.64 
3.05 0.191 10 9.07 
5.95 0.192 10 9.12 
Average Concentration [NH2Cl] mg/L as Cl2  9.33 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 95 9 111764.706 1 0
1 0.63 6.0 12 3 0
2 1.08 10.3 197 31 0 0 2982.35294 0.02668421 -1.5737456
3 2.2 20.9 tntc 58 0 0 682.352941 0.00610526 -2.2142956
4 4.22 40.2 71 11 0 0 83.5294118 0.00074737 -3.1264653


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 30.1 Final temp (°C) 30.1 
Initial pH 7.05 Final pH 7.10 
Initial abs. 0.196 Final abs. 0.208  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.196 10 9.31 
0.23 0.180 10 8.55 
3.77 0.204 10 9.69 
4.00 0.205 10 9.74 
6.22 0.209 10 9.93 
6.78 0.208 10 9.88 
Average Concentration [NH2Cl] mg/L as Cl2  9.52 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 108 1270588.24 1 0
1 2.08 13.0 tntc 166 15 185882.353 0.1462963 -0.8347667
2 5.13 32.0 tntc x x 2
3 10.03 62.5 tntc tntc 98 13 11529.4118 0.00907407 -2.0421977
4 15.07 93.9 tntc tntc 22 1 2588.23529 0.00203704 -2.6910011


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.2 Final temp (°C) 20.3 
Initial pH 7.05 Final pH 7.21 
Initial abs. 0.132 Final abs. 0.122  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.132 10 6.27 
0 0.124 10 5.89 
0 0.142 10 6.75 
1.92 0.140 10 6.65 
5.33 0.125 10 5.94 
10.33 0.134 10 6.37 
14.90 0.130 10 6.18 
25.33 0.122 10 5.80 
Average Concentration [NH2Cl] mg/L as Cl2  6.23 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 134 17 178823.529 1 0
1 2.45 17.5 tntc 47 2 55294.1176 0.30921053 -0.5097457
2 4.08 29.1 tntc 131 20 0 19470.5882 0.10888158 -0.9630456
3 6.47 46.1 tntc tntc 84 6 9882.35294 0.05526316 -1.2575643
4 10.02 71.4 tntc 52 0 x 611.764706 0.00342105 -2.4658402


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.0 Final temp (°C) 20.2 
Initial pH 5.99 Final pH 6.00 
Initial abs. 0.153 Final abs. 0.148  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.153 10 7.27 
0.67 0.150 10 7.13 
4.17 0.135 10 6.41 
7.80 0.160 10 7.60 
11.37 0.154 10 7.32 
15.52 0.148 10 7.03 
Average Concentration [NH2Cl] mg/L as Cl2  7.13 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 31 364705.882 1 0
1 2.58 9.7 tntc 51 16 124117.647 0.34032258 -0.4681092
2 5.17 19.4 tntc tntc 79 6 92941.1765 0.25483871 -0.5937346
3 10.18 38.1 tntc tntc 148 18 19294.1176 0.05290323 -1.2765178
4 19.4 72.7 tntc tntc 21 3 2470.58824 0.00677419 -2.1691424

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.0 Final temp (°C) 20.2 
Initial pH 6.06 Final pH 6.17 
Initial abs. 0.083 Final abs. 0.076  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.083 10 3.94 
0.53 0.075 10 3.56 
3.98 0.081 10 3.85 
8.02 0.084 10 3.99 
11.45 0.075 10 3.56 
19.67 0.078 10 3.71 
26.3 0.076 10 3.61 
Average Concentration [NH2Cl] mg/L as Cl2  3.75 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 22 258823.529 1 0
1 2.33 10.4 tntc 141 14 165882.353 0.64090909 -0.1932036
2 5.33 23.8 tntc 183 39 0 33705.8824 0.13022727 -0.8852981
3 10.42 46.5 tntc tntc tntc 33 3882.35294 0.015 -1.8239087
4 20 89.3 tntc tntc 34 4 400 0.00154545 -2.8109438


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.0 Final temp (°C) 19.9 
Initial pH 7.10 Final pH 7.26 
Initial abs. 0.097 Final abs. 0.092  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.097 10 4.61 
0 0.098 10 4.66 
0.50 0.098 10 4.66 
6.10 0.091 10 4.32 
10.67 0.088 10 4.18 
21.73 0.092 10 4.37 
Average Concentration [NH2Cl] mg/L as Cl2  4.47 
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Inactivation of CVB5 with Monochloramine, Experiment #52 
Date: 02/12/2013 






Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 28 1 32941.1765 1 0
1 10.38 107.8 6 0
2 29.43 305.6 0 0 0
3 40.47 420.2 0 0 0
4 45.47 472.1 0 0 0
Initial Conditions Final Conditions 
Initial temp  (°C) 19.8 Final temp (°C) 20.0 
Initial pH 8.05 Final pH 8.09 
Initial abs. 0.220 Final abs. 0.219  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.220 10 10.45 
0.7 0.221 10 10.50 
11.83 0.240 10 11.40 
28.73 0.216 10 10.26 
40.30 0.194 10 9.22 
43.70 0.220 10 10.45 
46.83 0.219 10 10.40 
Average Concentration [NH2Cl] mg/L as Cl2  10.38 
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Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 53 2 62352.9412 1 0
1 10.57 117.4 66 7 7764.70588 0.1245283 -0.9047319
2 29.67 329.4 tntc x 1
3 40.83 453.3 tntc 28 x 329.411765 0.00528302 -2.2771178
4 45.68 507.2 42 7 0 49.4117647 0.00079245 -3.1010266


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.8 Final temp (°C) 20.0 
Initial pH 9.99 Final pH 10.02 
Initial abs. 0.234 Final abs. 0.227  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.234 10 11.12 
0.83 0.234 10 11.12 
12.13 0.234 10 11.12 
28.97 0.242 10 11.50 
41.15 0.227 10 10.78 
43.90 0.238 10 11.31 
47.08 0.227 10 10.78 
Average Concentration [NH2Cl] mg/L as Cl2  11.10 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 198 24 257647.059 1 0
1 5.12 38.6 tntc 156 183529.412 0.71232877 -0.1473195
2 9.93 74.9 tntc tntc 44 19 137647.059 0.53424658 -0.2722583
3 36.47 275.0 tntc tntc 165 21 22058.8235 0.08561644 -1.0674428
4 64.07 483.1 tntc 162 10 2 1905.88235 0.00739726 -2.1309291

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 9.9 
Initial pH 8.07 Final pH 8.08 
Initial abs. 0.153 Final abs. 0.143  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.153 10 7.27 
0.68 0.164 10 7.79 
6.52 0.180 10 8.55 
9.15 0.153 10 7.27 
37.8 0.166 10 7.89 
65.53 0.152 10 7.22 
86.47 0.143 10 6.79 
Average Concentration [NH2Cl] mg/L as Cl2  7.54 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 73 x 85882.3529 1 0
1 5.2 39.2 tntc 45 8 52941.1765 0.61643836 -0.2101103
2 10.08 76.0 tntc tntc 37 8 43529.4118 0.50684932 -0.2951211
3 36.73 276.9 tntc tntc 178 34 30470.5882 0.35479452 -0.4500231
4 64.28 484.7 tntc tntc 151 21 10117.6471 0.11780822 -0.9288244
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 9.9 
Initial pH 9.98 Final pH 9.88 
Initial abs. 0.144 Final abs. 0.159  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.144 10 6.84 
1.1 0.152 10 7.22 
6.8 0.179 10 8.50 
9.33 0.155 10 7.36 
37.83 0.166 10 7.89 
65.63 0.156 10 7.41 
86.76 0.159 10 7.55 
Average Concentration [NH2Cl] mg/L as Cl2  7.54 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 123 x 144705.882 1 0
1 6.33 30.2 tntc 78 4 91764.7059 0.63414634 -0.1978105
2 29.7 141.6 tntc 101 6 0 11882.3529 0.08211382 -1.0855837
3 75.25 358.7 tntc 172 28 0 2658.82353 0.01837398 -1.7357967
4 118.95 567.0 x 5 0 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.0 Final temp (°C) 9.8 
Initial pH 6.9 Final pH 6.5 
Initial abs. 0.100 Final abs. 0.098  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.100 10 4.75 
0.68 0.105 10 4.99 
6.52 0.101 10 4.80 
9.15 0.100 10 4.75 
37.80 0.098 10 4.66 
65.53 0.098 10 4.66 
Average Concentration [NH2Cl] mg/L as Cl2  4.77 
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Inactivation of CVB5 with Monochloramine, Experiment #57 
Date: 02/18/2013 









Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 tntc 78 8 917647.059 1 0
1 5.1 30.8 x x x
2 10.15 61.2 tntc 128 x 0 15058.8235 0.01641026 -1.7848846
3 15.5 93.5 tntc 79 x x 929.411765 0.00101282 -2.9944675
4 19.67 118.7 tntc x x


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.8 Final temp (°C) 20.1 
Initial pH 7.01 Final pH 7.11 
Initial abs. 0.131 Final abs. 0.129  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.131 10 6.22 
8.13 0.121 10 5.75 
16.68 0.127 10 6.03 
21.17 0.127 10 6.03 
26.67 0.129 10 6.13 
Average Concentration [NH2Cl] mg/L as Cl2  6.03 
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Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 tntc 51 600000 1 0
1 5.33 26.9 tntc tntc 27 317647.059 0.52941176 -0.2762064
2 19.95 100.6 tntc 228 x 0 26823.5294 0.04470588 -1.3496353
3 60.52 305.2 182 94 36 0 2533.76471 0.00422294 -2.374385
4 88 443.7 x x 0


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 19.8 Final temp (°C) 20.2 
Initial pH 8.02 Final pH 8.13 
Initial abs. 0.103 Final abs. 0.107  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.103 10 4.89 
8.30 0.105 10 4.99 
17.00 0.105 10 4.99 
21.45 0.109 10 5.18 
59.03 0.103 10 4.89 
82.73 0.111 10 5.27 
113.83 0.107 10 5.08 
Average Concentration [NH2Cl] mg/L as Cl2  5.04 
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Inactivation of CVB5 with Monochloramine, Experiment #59 
Date: 02/20/2013 










Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 40 0 47058.8235 1 0
1 5.72 30.5 x x x
2 10.12 54.0 x x x x
3 15.33 81.8 tntc tntc 53 6 623.529412 0.01325 -1.8777841
4 26.05 139.0 47 0 55.2941176 0.001175 -2.9299621

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 29.9 Final temp (°C) 29.7 
Initial pH 8.00 Final pH 8.02 
Initial abs. 0.104 Final abs. 0.114  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.104 10 4.94 
0.73 0.115 10 5.46 
7.27 0.117 10 5.56 
16.67 0.112 10 5.32 
27.48 0.112 10 5.32 
33.83 0.114 10 5.42 
Average Concentration [NH2Cl] mg/L as Cl2  5.34 
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Inactivation of CVB5 with Monochloramine, Experiment #60 
Date: 02/20/2013 








Sample Time (min) CT 0 -1 -2 -3 -4 Count N/No Log(N/No)
No 0 0.0 34 4 40000 1 0
1 6.03 30.3 x x x
2 10.5 52.8 tntc tntc 25 x 2941.17647 0.07352941 3.46852108
3 15.57 78.3 188 19 0 0 222.352941 0.00555882 2.34704288
4 26.27 132.1 38 1 0 44.7058824 0.00111765 -2.9516953

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 29.9 Final temp (°C) 29.7 
Initial pH 7.98 Final pH 8.03 
Initial abs. 0.106 Final abs. 0.103  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.106 10 5.04 
0.87 0.109 10 5.18 
7.58 0.103 10 4.89 
10.03 0.107 10 5.08 
16.90 0.108 10 5.13 
27.75 0.105 10 4.99 
34.33 0.103 10 4.89 
Average Concentration [NH2Cl] mg/L as Cl2  5.03 
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Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 123 x 144705.882 1 0
1 10.33 70.0 tntc 78 4 91764.7059 0.63414634 -0.1978105
2 19.95 135.1 tntc 141 6 0 16588.2353 0.11463415 -0.940686
3 40.57 274.8 tntc 172 48 3 3835.29412 0.02650407 -1.5766875
4 59.87 405.5 x 5 0 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.6 Final temp (°C) 10.0 
Initial pH 7.93 Final pH 7.92 
Initial abs. 0.138 Final abs. 0.143  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.138 10 6.56 
0 0.144 10 6.84 
10.02 0.143 10 6.79 
19.8 0.140 10 6.65 
40.33 0.143 10 6.79 
59.23 0.147 10 6.98 
107.8 0.143 10 6.79 
Average Concentration [NH2Cl] mg/L as Cl2  6.77 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 Count N/No Log(N/No)
No 0 0.0 142 27 4 242352.941 1 0
1 24.53 217.6 tntc 101 12 2 118823.529 0.49029126 -0.3095458
2 44.83 397.6 tntc 94 8 0 11058.8235 0.04563107 -1.3407394
3 58.5 518.9 tntc tntc 35 0 4117.64706 0.01699029 -1.7697992
4 70.95 629.3 tntc tntc 24 2823.52941 0.01165049 -1.933656


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 10.0 
Initial pH 8.02 Final pH 8.20 
Initial abs. 0.183 Final abs. 0.173  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.183 10 8.69 
0.98 0.176 10 8.36 
27.32 0.210 10 9.98 
48.85 0.180 10 8.55 
57.35 0.193 10 9.22 
69.23 0.191 10 9.07 
129.28 0.173 10 8.22 
Average Concentration [NH2Cl] mg/L as Cl2  8.87 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 37 4 435294.118 1 0
1 2.08 17.5 173 19 3 213529.412 0.49054054 -0.3093251
2 7.23 61.0 tntc 94 11 2 110588.235 0.25405405 -0.5950739
3 10.25 86.4 tntc tntc 39 5 45882.3529 0.10540541 -0.9771371
4 19.9 167.8 tntc 114 31 2494.11765 0.00572973 -2.2418659
5 34 286.7 tntc 86 1011.76471 0.00232432 -2.6337033


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.8 Final temp (°C) 10.0 
Initial pH 6.1 Final pH 6.21 
Initial abs. 0.184 Final abs. 0.177  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.184 10 8.74 
0 0.182 10 8.65 
3.03 0.179 10 8.50 
8.53 0.175 10 8.31 
11.63 0.166 10 7.89 
20.80 0.176 10 8.36 
28.92 0.181 10 8.60 
38.92 0.177 10 8.41 
Average Concentration [NH2Cl] mg/L as Cl2  8.43 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 18 0 211764.706 1 0
1 10.6 96.2 x 62 10 72941.1765 0.34444444 -0.4628808
2 32.25 292.8 x 28 0 32941.1765 0.15555556 -0.8081145
3 65.88 598.2 tntc 104 24 0 5 2023.52941 0.00955556 -2.0197441
4 104.92 952.6 tntc x 1
5 127.48 1157.5 91 9 107.058824 0.00050556 -3.2962311


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.6 Final temp (°C) 10.0 
Initial pH 8.0 Final pH 8.08 
Initial abs. 0.189 Final abs. 0.179  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.189 10 8.98 
1.28 0.201 10 9.55 
9.17 0.194 10 9.22 
33.15 0.190 10 9.03 
67.22 0.197 10 9.36 
106.32 0.188 10 8.93 
127.16 0.191 10 9.07 
138.85 0.179 10 8.50 
Average Concentration [NH2Cl] mg/L as Cl2  9.08 
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Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 tntc 30 352941.176 1 0
1 14.92 201.5 tntc 46 0 54117.6471 0.15333333 -0.8143634
2 40 540.1 193 5 0 22705.8824 0.06433333 -1.1915639
3 81.03 1094.2 tntc 48 5 5647.05882 0.016 -1.79588
4 121.23 1637.0 tntc 74 10 870.588235 0.00246667 -2.6078895



















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 10.2 
Initial pH 9.99 Final pH 9.90 
Initial abs. 0.286 Final abs. 0.283  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.286 10 13.59 
0 0.285 10 13.54 
14.23 0.286 10 13.59 
30.08 0.288 10 13.68 
57.35 0.285 10 13.54 
78.30 0.277 10 13.16 
128.80 0.284 10 13.49 
160.90 0.283 10 13.44 
Average Concentration [NH2Cl] mg/L as Cl2  13.50 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 tntc 69 0 811764.706 1 0
1 14.45 94.4 185 35 314705.882 0.38768116 -0.4115253
2 30.72 200.7 tntc 93 14 109411.765 0.13478261 -0.8703661
3 55.42 362.0 tntc tntc 44 51764.7059 0.06376812 -1.1953964
4 89.9 587.2 tntc tntc 97 19 16882.3529 0.0207971 -1.6819972
5 121 790.4 tntc 92 4 1082.35294 0.00133333 -2.8750613


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 10.2 
Initial pH 7.96 Final pH 7.94 
Initial abs. 0.135 Final abs. 0.133  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.135 10 6.41 
0 0.133 10 6.32 
13.42 0.141 10 6.70 
29.78 0.137 10 6.51 
57.03 0.137 10 6.51 
78.00 0.142 10 6.75 
118.40 0.142 10 6.75 
148.20 0.133 10 6.32 
Average Concentration [NH2Cl] mg/L as Cl2  6.53 
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Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 72 8 84705.8824 1 0
1 5.65 49.0 tntc 34 2 40000 0.47222222 -0.3258536
2 10.08 87.3 156 29 26235.2941 0.30972222 -0.5090276
3 15.25 132.1 tntc 82 10 9647.05882 0.11388889 -0.9435186
4 20.15 174.6 tntc tntc 75 8823.52941 0.10416667 -0.9822712
5 30.12 261.0 tntc tntc 21 2470.58824 0.02916667 -1.5351132
6 44.87 388.8 tntc 34 400 0.00472222 -2.3258536

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 10.3 
Initial pH 7.03 Final pH 7.28 
Initial abs. 0.188 Final abs. 0.187  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.188 10 8.93 
0 0.185 10 8.79 
6.33 0.181 10 8.60 
11.13 0.176 10 8.36 
16.08 0.176 10 8.36 
19.62 0.174 10 8.27 
23.07 0.184 10 8.74 
28.45 0.189 10 8.98 
40.80 0.184 10 8.74 
51.83 0.187 10 8.88 
Average Concentration [NH2Cl] mg/L as Cl2  8.67 
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Sample Time (min) CT 0 -1 -2 -3 -4 No N/No Log(N/No)
No 0 0.0 4 0 4705.88235 1 0
1 5.83 53.1 29 1 0 3411.76471 0.725 -0.139662
2 10.42 94.8 17 0 2000 0.425 -0.3716111
3 15.58 141.8 34 9 0 400 0.085 -1.0705811
4 20.35 185.2 61 30 2 212.352941 0.045125 -1.3455828
5 30.37 276.4 46 0 0 54.1176471 0.0115 -1.9393022
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.1 Final temp (°C) 10.1 
Initial pH 7.00 Final pH 7.20 
Initial abs. 0.195 Final abs. 0.185  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.195 10 9.26 
0 0.195 10 9.26 
6.63 0.188 10 8.93 
11.46 0.188 10 8.93 
16.40 0.191 10 9.07 
19.92 0.197 10 9.36 
28.87 0.194 10 9.22 
43.75 0.191 10 9.07 
52.17 0.185 10 8.79 
Average Concentration [NH2Cl] mg/L as Cl2  9.10 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 125 18 0 179411.765 1 0
1 6.35 56.8 69 12 81176.4706 0.45245902 -0.3444208
2 10.13 90.7 tntc 53 62352.9412 0.34754098 -0.458994
3 15.28 136.8 tntc tntc 21 24705.8824 0.13770492 -0.8610505
4 20.3 181.7 tntc tntc 108 12705.8824 0.07081967 -1.1498461
5 30.28 271.1 tntc tntc 45 5294.11765 0.0295082 -1.5300573
6 40.07 358.7 tntc tntc


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.9 Final temp (°C) 9.9 
Initial pH 6.10 Final pH 6.00 
Initial abs. 0.188 Final abs. 0.193  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.188 10 8.93 
0.63 0.184 10 8.74 
7.83 0.200 10 9.50 
11.83 0.188 10 8.93 
17.40 0.194 10 9.22 
22.67 0.177 10 8.41 
29.70 0.198 10 9.41 
39.30 0.174 10 8.27 
48.60 0.193 10 9.17 
Average Concentration [NH2Cl] mg/L as Cl2  8.95 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 tntc 39 0 458823.529 1 0
1 6.62 54.1 134 18 184705.882 0.4025641 -0.395165
2 10.62 86.8 tntc 64 75294.1176 0.16410256 -0.7848846
3 15.35 125.4 tntc tntc 24 28235.2941 0.06153846 -1.2108534
4 20.4 166.7 tntc tntc 184 21647.0588 0.04717949 -1.3262468
5 30.5 249.2 tntc tntc 57 6705.88235 0.01461538 -1.8351898
6 40.43 330.4 tntc tntc


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.9 Final temp (°C) 9.9 
Initial pH 6.00 Final pH 6.15 
Initial abs. 0.181 Final abs. 0.174  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.181 10 8.60 
0.83 0.171 10 8.12 
12.17 0.168 10 7.98 
17.72 0.164 10 7.79 
23.10 0.173 10 8.22 
29.97 0.178 10 8.46 
39.58 0.167 10 7.93 
48.72 0.174 10 8.27 
Average Concentration [NH2Cl] mg/L as Cl2  8.17 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0 77 16 0 160901.054 1 0
1 25.68 227.046714 88 7 103529.412 0.64343526 -0.1914951
2 59.67 527.565321 tntc 54 4 63529.4118 0.39483527 -0.4035841
3 103.85 918.177619 tntc 142 28 26304.3832 0.16348173 -0.7865308
4 165.52 1463.42571 tntc 32 2 3764.70588 0.02339765 -1.6308278
5 179.72 1588.97334 tntc x 27 3176.47059 0.01974176 -1.7046141

















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.9 Final temp (°C) 10.1 
Initial pH 10.01 Final pH 9.97 
Initial abs. 0.189 Final abs. 0.176  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.189 10 8.98 
2.72 0.185 10 8.79 
27.17 0.189 10 8.98 
50.50 0.173 10 8.22 
92.40 0.203 10 9.64 
128.08 0.193 10  9.17 
157.30 0.177 10 8.41 
178.13 0.190 10 9.03 
210.12 0.176 10 8.36 
Average Concentration [NH2Cl] mg/L as Cl2  8.17 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 42 4 494117.647 1 0
1 25.97 310.5 35 1 411764.706 0.833333333 -0.0791812
2 49.3 589.4 tntc 176 23 238823.529 0.483333333 -0.3157533
3 91.2 1090.4 tntc 23 3 27058.8235 0.054761905 -1.2615215
4 128.35 1534.5 tntc 61 7 7176.47059 0.01452381 -1.8379195
5 155.62 1860.5 tntc 17 2 2000 0.004047619 -2.3928004
6 180.02 2152.3 155 16 185.294118 0.000375 -3.4259687



















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 9.9 Final temp (°C) 10.1 
Initial pH 10.02 Final pH 10.02 
Initial abs. 0.245 Final abs. 0.252  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.245 10 11.64 
3.00 0.250 10 11.88 
27.32 0.251 10 11.92 
50.95 0.252 10 11.97 
92.73 0.238 10 11.31 
126.58 0.255 10  12.11 
157.75 0.266 10 12.64 
178.47 0.256 10 12.16 
210.38 0.252 10 11.97 
Average Concentration [NH2Cl] mg/L as Cl2  11.96 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 70 3 823529.412 1 0
1 5.67 64.4 126 16 1 168235.294 0.20428571 -0.689762
2 10.67 121.3 tntc 73 12 85882.3529 0.10428571 -0.9817752
3 20.77 236.0 tntc 111 16 15941.1765 0.01935714 -1.7131587
4 27.48 312.3 tntc 63 6 7411.76471 0.009 -2.0457575
5 36.23 411.7 tntc 76 14 894.117647 0.00108571 -2.9642844
6 40.5 460.3 tntc 40 6 470.588235 0.00057143 -3.243038
7 49.72 565.0 tntc 21 0 247.058824 0.0003 -3.5228787


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.0 Final temp (°C) 9.9 
Initial pH 6.10 Final pH 6.22 
Initial abs. 0.234 Final abs. 0.246  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.234 10 11.12 
0 0.232 10 11.02 
3.07 0.228 10 10.83 
11.52 0.235 10 11.16 
24.47 0.252 10 11.97 
38.15 0.242 10  11.50 
52.32 0.248 10 11.78 
58.07 0.236 10 11.21 
62.85 0.246 10 11.69 
Average Concentration [NH2Cl] mg/L as Cl2  11.36 
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Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 66 2 776470.588 1 0
1 6.33 79.8 108 6 1 127058.824 0.16363636 -0.7861202
2 10.28 129.6 tntc 51 0 60000 0.07727273 -1.1119738
3 15.1 190.4 tntc tntc 21 1 24705.8824 0.03181818 -1.4973246
4 25.3 319.0 tntc 81 11 9529.41176 0.01227273 -1.9110589
5 35.22 444.0 tntc 139 19 5 1935.29412 0.00249242 -2.603378
6 45.03 567.7 tntc 67 4 788.235294 0.00101515 -2.9934691
7 52.62 663.4 tntc 34 0 400 0.00051515 -3.288065


















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 10.0 Final temp (°C) 9.9 
Initial pH 7.16 Final pH 7.35 
Initial abs. 0.264 Final abs. 0.268  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.264 10 12.54 
0 0.264 10 12.54 
25.08 0.274 10 13.02 
38.69 0.256 10 12.16 
52.73 0.266 10 12.64 
58.23 0.252 10  11.97 
72.73 0.279 10 13.25 
84.3 0.268 10 12.73 
Average Concentration [NH2Cl] mg/L as Cl2  12.61 
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Inactivation of CVB5 with Dichloramine, Experiment #75 
Date: 03/19/2013 







Sample Time (min) CT 0 -1 -2 -3 -4 -5 No N/No Log(N/No)
No 0 0.0 tntc 48 12 564705.882 1 0
1 4.92 41.3 tmtc tntc 34 400000 0.70833333 -0.1497623
2 14.67 123.3 tntc x 31 401034.929 0.71016602 -0.1486401
3 20.53 172.5 tntc tntc 18 253521.127 0.44894366 -0.3478082
4 31.85 267.6 tntc tntc x 0
















CVB5 Survival Ratio vs. CT 
Initial Conditions Final Conditions 
Initial temp  (°C) 20.0 Final temp (°C) 20.2 
Initial pH 5.99 Final pH 5.87 
Initial abs. 0.174 Final abs. 0.188  
 
   Time (min) Absorbance Dilution Factor Concentration [NH2Cl] mg/L as Cl2 
0 0.174 10 8.27 
0 0.168 10 7.98 
1.83 0.168 10 7.98 
10.40 0.168 10 7.98 
19.78 0.184 10 8.74 
30.85 0.188 10  8.93 
41.47 0.188 10 8.93 
Average Concentration [NH2Cl] mg/L as Cl2  8.40 
